Document:

EX-10.98

Exhibit 10.98

Approved By: Board of Directors (including Compensation Committee)

Approval Date: September 1, 2008

ALPHARMA INC. EXECUTIVE CHANGE IN CONTROL PLAN

Amended and Restated Effective September 1, 2008

Purpose of the Plan

The purpose of the Alpharma Inc. Change in Control Plan (the “Plan”) is to provide certain
Executives with benefits that will assist them with their transition following a Change in Control.
The Plan was initially effective March 11, 2002, and was amended and restated effective April 5,
2004, January 1, 2005, January 29, 2007, January 1, 2008 and January 25, 2008. The Plan is being
amended and restated in its entirety effective September 1, 2008.

This Plan represents an amendment and restatement of all prior executive-level change in control
plans, practices or policies in effect at Alpharma or any of its Subsidiaries as of the effective
date hereof, and supersedes any and all such prior change in control plans, practices and policies.
Except as otherwise specified in the Plan all such prior change in control plans, practices and
policies are hereby discontinued and terminated, to the extent permitted by law. (This does not
supersede the Alpharma Inc. Employee Change in Control Plan).

Wherever any words are used herein in the masculine gender they shall be construed as though they
were also used in the feminine gender in all cases where they would so apply, and wherever any
words are used herein in the singular form they shall be construed as though they were also used in
the plural form in all cases where they would so apply.

SECTION I — DEFINITIONS

The following definitions shall apply for purposes of this Plan:

	1.1	 	“Acquiring Company” — Has the meaning provided in the definition of Change in Control.
	 
	1.2	 	“Alpharma” — Alpharma Inc., a Delaware Corporation.

1

 

	1.3	 	“Applicable Severance Multiple” is the number of months for which an Executive is entitled to
payments or benefits under Section 4.2. The Applicable Severance Multiples are as follows:

Chief Executive Officer — 36 months

Each member of the Leadership Team — 30 months

Each Vice President — 18 months

Each Director (employee title, not Board member) — 12 months

	1.4	 	“Benefit Continuation Period” -In the case of an Executive who receives a Change in Control
Benefit, his Benefit Continuation Period will be equal to the number of months in an
Executive’s Applicable Severance Multiple used under Section 4.2 to compute the Executive’s
Change in Control Benefit.
	 
	1.5	 	“Benefits Committee” shall consist of the: Executive Vice President & General Counsel;
Executive Vice President & Chief Financial Officer; Executive Vice President — Human Resources
and Communications; and any other individual (or employee of the Acquiring Company holding
substantially similar positions) appointed from time to time by the Board.
	 
	1.6	 	“Board” — The Board of Directors of Alpharma.
	 
	1.7	 	“Bonus Severance Amount” shall be equal to the Executive’s bonus or other cash incentive
awards (as in effect immediately preceding the date of the Change in Control event),
determined at 100% of his annual target rate, with an assumed 100% funding of any applicable
bonus pool. For this purpose, such annual bonus or other award amount shall be divided by 12,
in order to represent a monthly amount payable for the number of months in the Applicable
Severance Multiple.
	 
	1.8	 	“Change in Control” shall mean: (a) The acquisition by any person, entity or “group”
(“Acquiring Company”) within the meaning of Section 13(d) (3) or 14(d) (2) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) (excluding, for this purpose, Alpharma
or its Subsidiaries, or any employee benefit plan of Alpharma or its Subsidiaries which
acquires beneficial ownership of voting securities of Alpharma) of beneficial ownership
(within the meaning of Rule 13d-3 promulgated under the Exchange Act) of shares of Common
Stock of Alpharma sufficient to elect a majority of directors to the Board; (b) persons who,
as of September 1, 2008, constitute the Board (the

2

 

	 	 	“Incumbent Board”) cease for any reason to constitute at least a majority of the Board, provided
that any person becoming a director on the Board subsequent to September 1, 2008 whose election,
or nomination for election by Alpharma’s stockholders, was approved by a vote of at least a
majority of the directors on the Board then comprising the Incumbent Board shall be considered
as though such person were a member of the Incumbent Board; (c) approval by the stockholders of
Alpharma of a reorganization, merger or consolidation, in each case, with respect to which
persons who were the stockholders of Alpharma immediately prior to such reorganization, merger
or consolidation do not, immediately thereafter, beneficially own shares sufficient to elect a
majority of directors in the election of directors of the reorganized, merged or consolidated
company; or (d) a liquidation or dissolution of Alpharma (other than pursuant to the United
States Bankruptcy Code) or the conveyance, transfer or leasing of all or substantially all of
the assets of Alpharma to any person (it being understood that a Non-Qualifying Sale shall not
qualify as such a conveyance or transfer).
	 
	1.9	 	“Change in Control Benefits” — Has the meaning provided in Section 4.2.
	 
	1.10	 	“Chief Executive Officer” — Chief Executive Officer of Alpharma.
	 
	1.11	 	“Code” — The Internal Revenue Code of 1986, as amended. Any reference to a section in the
Code shall include the regulations and other guidance issued thereunder.
	 
	1.12	 	“Committee” — The Compensation Committee of the Board.
	 
	1.13	 	“Company” — Alpharma Inc. and its US Subsidiaries and any non-US Subsidiary whose Board of
Directors (or similar governing body) has adopted this plan, or any successor by merger,
consolidation or sale of assets.
	 
	1.14	 	“Constructive Termination” — A voluntary resignation following a Change in Control and
following an omission or action initiated by Alpharma, a Subsidiary or an Acquiring Company
which results in (a) a material reduction in the Executive’s compensation or a material
reduction in the basis upon which such Executive’s bonus or commission is determined, (b) the
Executive’s relocation to a base office or site which is more than 50 miles from the location
of the Executive’s office or site prior to the Change in Control, (c) the assignment of duties
substantially inconsistent with, or a substantial diminution of,

3

 

	 	 	the duties, responsibilities or status of the position that the Executive held prior to the
Change in Control, (d) a substantial reduction in benefits, or (e) a material change in the
reporting relationship which is detrimental to the Executive (including, without limitation,
a detrimental change in the position to which the Executive reports but not including,
without limitation, the termination or change in the person who held the position to whom
the Executive reported prior to the Change in Control).
	 
	1.15	 	“Employee” — A full-time (a person who is regularly scheduled to work a minimum of 30 hours
per week) permanent salaried or hourly employee of the Company, as determined by the
Committee. An Employee shall not include any individual classified by the Company as either a
temporary employee, a leased employee or an independent contractor (regardless of whether such
individual is classified or retroactively reclassified as an employee of the Company by any
person, entity or agency).
	 
	1.16	 	“Executive” — An Employee who is providing services to the Company in one of the following
capacities: the Chief Executive Officer, a member of the Leadership Team, an Employee holding
the title of Vice President or Director (not to be confused with a member of the Board) of the
Company or its Operating Divisions, or any other individual deemed by the Committee to be an
Executive.
	 
	1.17	 	“Executive Allowance” — The annual allowance (currently paid bi-weekly) for various fringe
benefits provided to the Executive under the Company’s Executive Allowance program, as
currently in effect and as amended from time to time, prior to a Change in Control (or, if
higher, prior to the Executive’s Termination Date).
	 
	1.18	 	“Involuntary Termination of Employment” — A Termination of Employment by the Company (other
than a Termination for Cause).
	 
	1.19	 	“Leadership Team” — Those officers of the Company that report directly to the Chief Executive
Officer and such other employees who the Chief Executive Officer, in his sole discretion,
determines are eligible to be classified as a member of the Leadership Team for purposes of
this Plan.
	 
	1.20	 	“Non Qualifying Sale” — A sale of (a) the stock or assets of a Subsidiary or the assets of an
Operating Division, or (b) assets of the Company; provided, however, that any sale

4

 

	 	 	under either (a) or (b) that is a sale of all or substantially all of the assets or stock of
the Company shall not be considered a Non Qualifying Sale.
	 
	1.21	 	“Operating Division” — The Company’s operating divisions, which for management or financial
purposes are reported as individual business segments.
	 
	1.22	 	“Plan” — The Alpharma Inc. Executive Change in Control Plan, as amended from time to time.
	 
	1.23	 	“Salary” — An Executive’s annual base salary immediately preceding his Termination Date, or,
if higher, the amount that was in effect at the time of the occurrence of a Change in Control.
In the United States, Salary shall include amounts contributed on behalf of the Executive to
a cafeteria plan or a cash or deferred arrangement and not includable in compensation under
Section 125 or 402(e)(3) of the Code. Salary shall also include cash amounts paid to an
Executive in lieu of fringe benefits, specifically including any Executive Allowance such
Executive was receiving immediately preceding his termination but excluding any commuter or
car/auto allowance. However, for the purpose of calculating monthly benefits payable as
“Salary” under Section 4.2, the total of the amounts listed above shall be divided by 12, in
order to represent a monthly amount payable for the number of months in the Applicable
Severance Multiple for such Executive. Salary shall exclude the following: commissions;
incentive compensation; bonuses; overtime; extended workweek premiums; cost-of-living
allowances; shift premiums; other premiums; deferred compensation; payments under advisory
agreements; any other special payments, fees, or allowances.
	 
	1.24	 	“Specified Employee” — An Employee who, as of the Employee’s Termination Date, is a key
employee of the Company within the meaning of Section 416(i)(1)(A)(i), (ii), or (iii) of the
Code (applied in accordance with the regulations thereunder and disregarding section
416(i)(5)) at any time during the 12-month period ending on a Specified Employee
Identification Date. If an Employee is a key employee as of a Specified Employee
Identification Date, the Employee is treated as a key employee for purposes of the Plan for
the entire 12-month period beginning on the Specified Employee Effective Date.

5

 

	1.25	 	“Specified Employee Effective Date” — The first day of the fourth month following the
Specified Employee Identification Date.
	 
	1.26	 	“Specified Employee Identification Date” — December 31.
	 
	1.27	 	“Subsidiary” — Any corporation in which Alpharma owns either directly or indirectly, more
than 50% of the voting stock.
	 
	1.28	 	“Termination Date” — The date an Executive’s active employment with the Company terminates as
a result of an Involuntary Termination of Employment or the date the Committee determines
there has been a Constructive Termination.
	 
	1.29	 	“Termination for Cause” — A Termination of Employment for reasons such as a conviction of a
felony, illegal or inappropriate use of drugs or alcohol, unsatisfactory attendance,
substantial and willful neglect of job duties, failure or inability to adequately perform job
duties, violation of any written company policy, disclosure of confidential information
regarding the Company or its operations, or the aiding or assisting of any person or entity
which is competitive with the Company or its successors. The determination of whether an
Executive is terminated for Cause or not for Cause shall be made by the Committee in its sole
discretion and shall be final and conclusive.
	 
	1.30	 	“Termination of Employment” — A termination of employment with the Company for any reason
other than by reason of retirement, death or disability provided that a transfer of employment
to the Acquiring Company or any of its affiliates shall not be a Termination of Employment
unless it constitutes a Constructive Termination.
	 
	1.31	 	“US Employee” — An Employee whose primary place of employment is in the United States.
	 
	1.32	 	“US Subsidiary” — Any Subsidiary incorporated in the United States.
	 
	1.33	 	“Waiver and Release” — A form of waiver and release provided by the Company which has the
effect of releasing the Company, its affiliates, officers, members of the Board and employees
from any and all claims, demands, causes of action, damages, expenses and liabilities, whether
known or unknown, which the Executive has or may later have against the Company or its
employee benefits plans, plan administrators, fiduciaries, or any other parties that may be
listed in such form of waiver and release, which relate in

6

 

	 	 	any way to his employment by the Company, or his separation from employment with the
Company, or any other matter at the time of Termination of Employment.

ARTICLE II — ELIGIBILITY

	2.1	 	Eligibility for Change in Control Benefits.

	 	(a)	 	Subject to Section 3.1, an Executive shall be eligible to receive
Change in Control Benefits specified under Article IV if concurrently with or
within the 24-month period following the Change in Control he has either (i) an
Involuntary Termination of Employment, or (ii) a Constructive Termination.
	 
	 	(b)	 	An Executive shall not be eligible for Change in Control Benefits if he
is subject to a collective bargaining agreement or comparable labor agreement or is
otherwise not permitted to participate pursuant to the laws of the jurisdiction
where he is employed.
	 
	 	(c)	 	A Non Qualifying Sale shall not be deemed a Change in Control and an
Executive shall not be eligible to receive Change in Control Benefits upon a Non
Qualifying Sale.

	2.2	 	Committee Discretion. Subject to Sections 8.3 and 8.5 hereof, the Committee shall
have full discretion to determine eligibility to receive benefits under this Plan. Such
discretion shall be exercised in accordance with the provisions set forth herein and in a
uniform and non-discriminatory fashion, and in accordance with Section 409A of the Code.

ARTICLE III — CONDITIONS

	3.1	 	Change in Control Benefits Conditions. The following are conditions to an Executive
receiving Change in Control Benefits:

	 	(a)	 	Termination Date on or after September 1, 2008;
	 
	 	(b)	 	Termination Date does not immediately follow a period during
which the Executive has not been actively at work due to leave of absence,
layoff or salary continuance, unless the Committee specifically designates the
condition as not applicable to the Executive;

7

 

	 	(c)	 	To the extent that an Executive claims that Constructive
Termination has occurred, such claim shall be made in writing to the Committee
within 90 days following the Constructive Termination event;
	 
	 	(d)	 	If requested by the Company or Acquiring Company, the Executive
shall remain employed with the Company or the Acquiring Company for up to six
months following the Change in Control; and
	 
	 	(e)	 	No later than 21 days after the Company delivers the Waiver and
Release to the Executive for signature (unless the Company explicitly provides
a longer review period), the Executive shall have delivered to the Company an
executed Waiver and Release and shall not have revoked it within the seven (7)
days after the execution thereof; provided, however, that if the period during
which the Executive has discretion to execute or revoke the Waiver and Release
straddles two taxable years of the Executive, then the Company shall make the
payments to which the Executive is entitled under Section 4.2 starting in the
second of such taxable years, regardless of which taxable year the Executive
actually delivers the executed Waiver and Release to the Company.

	 	 	 	To the extent the duration of the Change in Control Benefits is longer than any
notice period required under the laws of the jurisdiction in which an Executive is
employed, then such Change in Control Benefits shall be in lieu of such notice
period.

ARTICLE IV — CHANGE IN CONTROL BENEFITS

	4.1	 	General.
	 
	 	 	Subject to Section 6.1, an Executive who is eligible under Section 2.1 to receive
Change in Control Benefits and who satisfies the conditions in Section 3.1 shall receive the
amount of Change in Control Benefits specified under Section 4.2 payable in accordance with
Article VII and those other benefits as specified in Article V.

8

 

	4.2	 	Amount of Change in Control Benefits.
	 
	 	 	An Executive who satisfies the eligibility requirements under Section
2.1 shall receive the following Change in Control benefits (“Change in
Control Benefits”):

	 	(a)	 	Monthly payments of Salary for such number of months following
the Termination Date equal to such Executive’s Applicable Severance Multiple.
Additionally, he shall receive his Bonus Severance Amount monthly for such
number of months equal to such Executive’s Applicable Severance Multiple.
	 
	 	(b)	 	(i) reasonable and customary outplacement services for a period
not to extend beyond such Executive’s Applicable Severance Multiple, which are
consistent with the Company’s past practices; and (ii) accrued but unused
vacation pay (up to the Termination Date) consistent with the Company’s legal
requirements concerning such payments.

	4.3	 	Bonus and Incentive Awards.
	 
	 	 	Any bonus or incentive award payable under the terms of this Plan shall be in addition to
any bonus or incentive award otherwise payable under any then-existing bonus or incentive
award plans during the year in which the Change in Control event occurs. Notwithstanding
anything herein to the contrary, upon a Change in Control event, an Executive’s target
annual bonus or incentive award amounts or rates may not be reduced.

ARTICLE V — OTHER BENEFIT PROVISIONS

	5.1	 	Medical, Dental, Vision, Prescription Drug, and/or Life Insurance Coverage.
	 
	 	 	An Executive shall be entitled to continued coverage under the medical, dental, vision,
prescription drug, accidental death and dismemberment and/or life insurance benefits
(employee life and dependent life) plans sponsored by the Company under which the Executive
is covered and as in effect on the Executive’s Termination Date (including medical, dental,
vision and prescription drug coverage for the Executive’s then covered dependents, if any)
for the duration of the applicable Benefit Continuation Period. Such coverage shall be
equal to the coverage offered to the active Executives of the Company or Acquiring Company,
as the case may be, during such Benefit Continuation Period and

9

 

	 	 	shall be at the same cost to the Executive as is applicable to such active Executives during
the Benefit Continuation Period. In no event shall an Executive be entitled to add
dependents to his medical, dental, vision or prescription drug coverage after his
Termination Date, except for US Employees as would otherwise be allowed by the Consolidated
Omnibus Budget Reconciliation Act of 1985 (“COBRA”).
	 
	 	 	At the end of the Benefit Continuation Period, an Executive who is a US Employee may elect
to continue medical, dental, vision and prescription drug pursuant to the continuation
coverage provisions under COBRA. The period for which such Executive is eligible for COBRA
coverage shall not be reduced by the medical, dental, vision and/or prescription drug
coverage which he receives during the Benefit Continuation Period. At the end of the
Benefit Continuation Period, accidental death and dismemberment and life insurance (employee
life and dependent life) benefits shall cease.
	 
	 	 	An Executive’s participation in the healthcare flexible spending account after his or her
Termination Date shall be administered in accordance with COBRA.

	5.2	 	Retiree Medical Benefits.

	 	(a)	 	An Executive who is eligible to retire and who is eligible for retiree health
coverage as of his Termination Date shall be provided retiree health coverage in
accordance with the provisions of the applicable plans rather than the coverage
described in this Article V.
	 
	 	(b)	 	An Executive who is eligible to retire and who is not eligible for retiree
health insurance as of his Termination Date shall be eligible for medical, dental,
vision and prescription drug coverage provided for in Section 5.1 for the Benefit
Continuation Period and the COBRA coverage period in accordance with the provisions of
this Article V.

	5.3	 	Retirement Plans.
	 
	 	 	In the event an Executive becomes eligible to receive Change in Control Benefits, the
benefit payments under this Plan shall not be considered for purposes of computing benefits
under the Alpharma Inc. Pension Plan and the Alpharma Inc. Supplemental

10

 

	 	 	Pension Plan or any similar pension or retirement plan. An Executive shall not be eligible
to actively participate under any such Plans after his Termination Date.

	5.4	 	Savings Plan and Stock Purchase Plan
	 
	 	 	In the event an Executive becomes eligible to receive Change in Control Benefits, the
benefit payments under this Plan shall not be considered for purposes of computing benefits
under any defined contribution plan or stock purchase plan sponsored by the Company
including the Employee Stock Purchase Plan, the Alpharma Inc. Savings Plan and the Alpharma
Inc. Supplemental Savings Plan (or the 2005 or 2007 Supplemental Savings Plans). An
Executive shall not be eligible to actively participate under any of these Plans after his
Termination Date.

	5.5	 	Long Term Incentive Awards.

	 	(a)	 	As permitted under Section 8 of the Alpharma Inc. 1997 Incentive Stock Option
and Appreciation Rights Plan, as amended (“Stock Option Plan”), upon the occurrence of
a Change in Control, all Options and Units (as defined under the Stock Option Plan)
held by an Executive shall become immediately exercisable by the optionee and grantee,
respectively, and shall remain exercisable for the lesser of (i) the length of time
during which the Option or Unit, as the case may be, may be exercised or (ii) the
maximum period permitted under the Stock Option Plan.
	 
	 	(b)	 	As permitted under Article 16 of the Alpharma Inc. 2003 Omnibus Incentive
Compensation Plan (“Omnibus Plan”), upon the occurrence of a Change in Control, all
NQSOs and ISOs (both as defined under the Omnibus Plan) held by an Executive shall
become immediately exercisable by the optionee and shall remain exercisable for the
lesser of (i) the length of time during which the NQSO or ISO may be exercised and (ii)
the maximum period permitted under the Omnibus Plan.
	 
	 	(c)	 	As permitted under Article 16 of the Omnibus Plan, upon the occurrence of a
Change in Control followed by either (i) an Involuntary Termination of Employment or a
Constructive Termination within twenty-four (24) months after

11

 

	 	 	 	the date of said Change in Control, or (ii) the purchase or other acquisition by the
entity effecting such Change in Control (either as part of the transaction giving
rise to the Change in Control or in a separate transaction or transactions or in a
combination of such transactions) of all or substantially all of the issued and
outstanding Class A and Class B common stock, (x) all Restricted Stock (as defined
under the Omnibus Plan) held by an Executive in the employ of the Company as of the
day immediately prior to the date upon which condition (i) or (ii) is first
satisfied shall immediately vest and become the property of said Executive and (y)
all Performance Shares and Performance Units (as defined under the Omnibus Plan)
held by an Executive in the employ of the Company as of the day immediately prior to
the date upon which condition (i) or (ii) is first satisfied shall have a final
value computed on a date as close as practicable to the date upon which condition
(i) or (ii) is first satisfied and such sum shall thereupon be paid to the
Executive.
	 
	 	(d)	 	Notwithstanding anything herein to the contrary, the additional changes and
modifications to benefits granted under the Omnibus Plan not inconsistent with the
treatment of such benefits as set forth in this Section 5.5 may be made upon a Change
in Control pursuant to Section 4.2 of the Omnibus Plan.

	5.6	 	Other Plans.
	 
	 	 	An Executive’s participation in all other employee benefit plans sponsored by the Company
shall cease being effective as of the Executive’s Termination Date, unless such plans
provide otherwise.

	5.7	 	Terms of Other Plans.
	 
	 	 	Continued participation in any of the plans noted above shall be subject to the terms of
said plans; as in the past, the Company continues to retain the right to amend or terminate
such plans at any time in accordance with the terms of such plans.

ARTICLE VI — OTHER AGREEMENTS AND LAWS

	6.1	 	General.

12

 

	 	 	Notwithstanding anything to the contrary herein, to the extent that an Executive is party to
an employment agreement with the Company, the Executive shall be entitled to receive
benefits (taken individually) equal to the greater of (i) the benefits available under the
Plan, or (ii) the benefits available under such employment agreement, but in no event shall
the benefits be provided in an additive manner.
	 
	6.2	 	Local Laws.
	 
	 	 	Notwithstanding anything to the contrary herein, to the extent that an Executive satisfies
the conditions in Sections 2.1 and 3.1, and any such Executive is entitled to benefits at
the time of a Termination of Employment under applicable local law, which are more favorable
than the Change in Control Benefits available under the Plan or under Section 6.1, the
Executive shall receive only those benefits available under local law.

ARTICLE VII — PAYMENT

	7.1	 	Method of Payment.

	 	(a)	 	Change in Control Benefits under Section 4.2 shall be paid to an Executive in
installments in accordance with the Company’s standard payroll cycles beginning with
the first payroll period immediately after his Termination Date and continuing for the
applicable Benefit Continuation Period. Notwithstanding the foregoing, Change in
Control Benefits payable to an Executive who is a Specified Employee shall begin no
earlier than six months after his Termination Date if the Company determines that the
delay is necessary to comply with Section 409A of the Code.
	 
	 	(b)	 	If an Executive dies after his Involuntary Termination of Employment or
Constructive Termination but before receiving the total amount of his Change in Control
Benefit, such benefit will instead be paid in a lump sum to the Executive’s surviving
spouse, if any, and otherwise to the Executive’s estate commencing as soon as
administratively feasible after the date of death.

SECTION VIII — ADMINISTRATION

	8.1	 	The Committee.
	 
	 	 	The Committee shall have the complete authority to: (a) determine eligibility for benefits

13

 

	 	 	in accordance with the provisions of the Plan, (b) construe in good faith the terms of the
Plan, and (c) control and manage the operation of the Plan.
	 
	8.2	 	Administrative Rules.
	 
	 	 	Subject to the limitations of the Plan, the Committee from time to time shall establish
rules for the administration and interpretation of the Plan and the transaction of its
business. The determination of the Committee as to any disputed question shall be
conclusive. All actions, decisions and interpretations of the Committee in administering
the Plan shall be conclusive. All actions, decisions and interpretations of the Committee
in administering the Plan shall be performed in good faith in a uniform and
non-discriminatory manner.
	 
	8.3	 	Delegation.
	 
	 	 	The Committee may, in its sole discretion, delegate some or all of its functions to third
parties and employ counsel and other agents and may procure such clerical, actuarial
accounting and other services as the Committee may require in carrying out the provisions of
the Plan.
	 
	8.4.	 	Indemnification.
	 
	 	 	The Company shall indemnify and hold harmless each member of the Committee against all
expenses and liabilities arising out of the Committee member’s service as such, excepting
only expenses and liabilities arising from the member’s own gross negligence or willful
misconduct.
	 
	8.5	 	Arbitration.
	 
	 	 	All disputes regarding the application of the definition of Constructive Termination and the
provisions of Section 409A of the Code shall be submitted to an Arbitration Panel whose
findings shall be binding on the Company and the Executive. For purposes of this Plan, the
term “Arbitration Panel” shall mean three (3) independent arbitrators, one of whom shall be
selected by the Company, one by the Executive and the third shall be selected by the two
other arbitrators. In the event that agreement cannot be reached on the selection of the
third arbitrator, such arbitrator shall be selected by the American Arbitration Association.
All arbitrators shall be selected from a list provided by the

14

 

	 	 	American Arbitration Association. All matters presented to the Arbitration Panel shall be
decided by majority vote. All costs of the arbitration, including the Executive’s attorneys’
fees, if any, shall be paid by the Company.
	 
	8.6	 	Claim Procedure.

	 	(a)	 	The Company will notify an Executive at the time of Termination of Employment
what benefits, if any, he will receive under the Plan. If an Executive believes that
he is entitled to receive additional benefits under the Plan he must submit a claim for
benefits in writing to the Committee. Any claim for benefits must be received by the
Committee within 60 days after the date of the Executive’s Terminated Employment. If a
claim for benefits under the Plan is denied in whole or in part, the claimant will
receive written notice of the denial within 90 days after the filing of the claim. The
notice will state the specific reason for the denial of benefits.
	 
	 	(b)	 	Any claimant whose claim for benefits is denied may request a review of the
decision denying his claim. The claimant or his duly authorized representative must
submit a written request for review to the Committee within 60 days after receiving the
notice of denial. When making a request for review, a claimant should state the
reasons why he believes the claim was improperly denied and should submit any documents
or information relevant to the claim.
	 
	 	(c)	 	The decision on review will be completed and furnished to the claimant in
writing within 60 days after receipt of the request for review. All decisions of the
Committee are final and binding. In unusual circumstances the Committee may require an
extension of time for deciding on a claim for benefits or a request for review.
Whenever there is a need for an extension of time, the Committee will notify the
claimant of the extension. In no event will such an extension exceed a period of 90
days in the case of the initial claim or 60 days in the case of the decision on review.
	 
	 	(d)	 	If the Committee fails to take any action required by it within the time limits
specified above, the claim shall be deemed denied as of the latest date by which such
action should have been completed.

15

 

ARTICLE IX — MISCELLANEOUS

	9.1	 	Amendment and Termination.

	 	(a)	 	Subject to Section 9.1(b) below, Alpharma, acting through its Board, reserves
the right to amend or modify the Plan, to terminate the Plan in its entirety, or to
terminate the participation in the Plan of any Subsidiary. The Board retains the
authority to adopt amendments to the Plan that significantly increase or decrease
benefit amounts, or are required to be adopted by the Board under the Code or
regulations thereunder. Subject to the foregoing, the Board has delegated to the
Benefits Committee the authority to adopt administrative amendments to the Plan,
provided, that such amendments do not involve a change in the costs or liability of
Alpharma or alter the benefits payable thereunder. Also subject to the foregoing, the
Board has delegated to the Compensation Committee the authority to adopt all other
amendments to the Plan, provided, that such amendments do not significantly increase or
decrease benefit amounts, or are required to be adopted by the Board under the Code or
the regulations thereunder.
	 
	 	(b)	 	Notwithstanding the foregoing Section 9.1(a): (i) any such amendment,
modification or termination shall not be applicable to an Executive who has already
been notified of a Termination of Employment, (ii) the Plan shall not be amended,
modified or terminated after the earlier of the date of the occurrence of (A) a Change
of Control or (B) the execution of a written contract or agreement which, if
consummated, would result in a Change of Control, and (iii) Alpharma may terminate the
Plan only to the extent permitted under Section 409A of the Code in such a way so as to
avoid having any tax or penalty be imposed upon any affected participant, or as
otherwise required to comply with applicable law.

	9.2	 	Parachute Payments.

	 	(a)	 	Notwithstanding anything in this Plan to the contrary, to the extent that the
Company (x) signs a definitive agreement on or prior to March 31, 2009 contemplating
the consummation of a Change in Control, or (y) there actually
occurs a Change in Control on or prior to March 31, 2009, or (z) a third party

16

 

	 	 	 	commences a tender offer on or prior to March 31, 2009 that is not approved by the
Board and results in a Change in Control after March 31, 2009, and in any such event
an Executive becomes entitled to receive payments in connection with such events
(x), (y) or (z) (whether pursuant to the terms of this Plan, or pursuant to any
other plan, arrangement or agreement, in general, a “Payment”) from (i) the Company,
(ii) any person whose actions result in a Change in Control, or (iii) any person
affiliated with the Company or such person (collectively, all such payments, the
“Total Payments”), that would result in Excess Parachute Payments subject to the
Excise Tax imposed by Section 4999 of the Code, then and only then will such
Executive be entitled to receive an Excise Tax Gross-Up Payment (as defined below).
The Company’s obligation to provide any such Excise Tax Gross-Up Payment in respect
of any of the above events (x), (y), or (z) shall continue beyond March 31, 2009.
Moreover, the Company shall make such payments in a manner so as to comply with
Section 409A of the Code.
	 
	 	(b)	 	“Excess Parachute Payments” shall mean “parachute payments” as defined in
Section 280G of the Code other than (1) health and life insurance benefits and
(2) payments attributable to any award, benefit or other compensation plan or program
based upon the number of full or fractional months of any restricted period (relating
thereto) which has elapsed prior to the date of the Change in Control. The terms of
any new or revised tax regulations relating to Excess Parachute Payments shall be
incorporated by reference herein.
	 
	 	(c)	 	“Excise Tax Gross-Up Payment.” If the Executive is entitled to receive an
Excise Tax Gross-Up Payment under Section 9.2(a) above, then the Acquiring Company
shall make an additional payment (a “Gross-Up Payment”) to the Executive in an amount
such that after payment by the Executive of all taxes (including any interest or
penalties imposed with respect to such taxes), including, without limitation, any
income taxes (and any interest and penalties imposed with respect thereto) and the
Excise Tax imposed upon the Gross-Up Payment, the Executive retains an amount of the
Gross-Up Payment equal to the Excise Tax imposed upon the Total Payments.

17

 

	9.3	 	Tax Withholding.
	 
	 	 	The Company shall withhold all required local, state and federal income taxes from any
benefits payable under this Plan.
	 
	9.4	 	Binding on Successors.
	 
	 	 	The obligations of the Company under the Plan shall be binding upon any organization which
shall succeed to all or substantially all of the assets of the Company, and the term
“Company,” whenever used in the Plan, shall mean and include any such organization after the
succession.
	 
	9.5	 	Applicable Law.

	 
	 	 	The Plan shall be governed by and construed in accordance with the
laws of the State of New Jersey (regardless of the laws that might
otherwise govern under applicable New Jersey principles of conflicts
of law.

	 
	9.6	 	 Contract Right of Executives. 
	 
	 	 	Subject to Section 9.1 above, the Board intends this Plan to
constitute an enforceable contract between the Company and each
Executive and intends this Plan to vest rights in such Executives as
third party beneficiaries.
	 
	9.7	 	Compensation.
	 
	 	 	For all purposes hereof, the determination of an Executive’s bonus or incentive award
amount, compensation, rate of base earnings, job grade or band, target award and similar
amounts or status shall be made based upon the amount in effect immediately preceding his
Termination Date, or, if higher, the amount that was in effect at the time of the occurrence
of a Change in Control.
	 
	9.8	 	Compliance with Section 409A. Notwithstanding anything herein to the contrary, (i)
if at the time of the Executive’s Termination of Employment with the Company, the Executive is
a “specified employee” as defined in Section 409A of the Code, and the deferral of the
commencement of any payments or benefits otherwise payable hereunder as a result of such
Termination of Employment is necessary in order to prevent the imposition of any accelerated
or additional tax under Section 409A of the Code, then the Company will defer the commencement
of the payment of any such payments or benefits

18

 

	 	 	hereunder (without any reduction in such payments or benefits ultimately paid or provided to
the Executive) until the date that is six (6) months following the Executive’s Termination
of Employment with the Company (or the earliest date as is permitted under Section 409A of
the Code) and (ii) if any other payments of money or other benefits due to the Executive
hereunder could cause the application of an accelerated or additional tax under Section 409A
of the Code, such payments or other benefits shall be deferred if deferral will make such
payment or other benefits compliant under Section 409A of the Code, or otherwise such
payment or other benefits shall be restructured, to the extent possible, in a manner,
determined by the Board, that does not cause such an accelerated or additional tax or result
in an additional cost to the Company. The Company shall consult with the Executive in good
faith regarding the implementation of the provisions of this Section 9.8; provided that
neither the Company nor any of its employees or representatives shall have any liability to
the Executive with respect thereto.

	 	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Alpharma Inc.
	 	 

19EX-10.99

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions.

Exhibit 10.99

DEVELOPMENT AND LICENSE AGREEMENT

BETWEEN

DURECT CORPORATION

AND

ALPHARMA IRELAND LIMITED

DATED AS OF

SEPTEMBER 19, 2008

CONFIDENTIAL

 

 

DEVELOPMENT AND LICENSE AGREEMENT

     THIS DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), dated September 19, 2008
(“Execution Date”), is entered into by and between Durect Corporation, a corporation
organized and existing under the laws of the State of Delaware, U.S.A. with a place of business at
2 Results Way, Cupertino, CA 95014 (“Durect”), and Alpharma Ireland Limited, a corporation
organized and existing under the laws of Ireland, having its registered office at Arthur Cox
Building, Earlsfort Terrace, Dublin 2, Ireland (“Alpharma”).

PRELIMINARY STATEMENTS

     A. Durect is the owner of a proprietary product for pain treatment consisting of a bupivacaine
transdermal patch as described below and certain patents and know-how relating thereto;

     B. Durect desires to have such product further developed and commercialized in the territory
specified below;

     C. Alpharma has capabilities in the development, manufacture, promotion, marketing and sales
of pharmaceutical products in the field of pain treatment in the specified territory; and

     D. Durect desires to grant certain exclusive rights to Alpharma in respect of such product in
the specified territory and related matters upon the terms and conditions hereinafter set forth.

AGREEMENT

     NOW THEREFORE, in consideration of the mutual covenants and agreements provided herein, and
other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

1. DEFINITIONS.

     As used in this Agreement, the following terms shall have the meanings set forth in this
Section 1:

CONFIDENTIAL

1

 

     1.1 “ANDA” means an abbreviated new drug application pursuant to Section 505(j) of the
FDC Act.

     1.2 “Affiliate” means, with respect to a Person, any Person that controls, is
controlled by or is under common control with such first Person. For purposes of this definition
only, “control” means (a) to possess, directly or indirectly, the power to direct the management or
policies of a Person, whether through ownership of voting securities, by contract relating to
voting rights or corporate governance, or (b) to own, directly or indirectly, fifty percent (50%)
or more of the outstanding voting securities or other ownership interest of such Person. An entity
will be an Affiliate for purposes of this Agreement only so long as it satisfies the definition set
forth herein.

     1.3 “Applicable Laws” means the applicable laws, rules and regulations, including any
rules, regulations, guidelines or other requirements of the Health Authorities, that may be in
effect from time to time.

     1.4
[ ** ].

     1.5 “Bupivacaine” means 1-butyl-N-(2,6-dimethylphenyl) piperidine-2-carboxamide,
including any and all pharmaceutically acceptable salts, solvates, prodrugs, esters, free base
forms, enantiomers (and racemic or other mixtures of said enantiomers) thereof.

     1.6 “cGMP” means current Good Manufacturing Practice for medicinal products for human
use as set forth in U.S. Code of Federal Regulations 21 CFR Part 210, 211 et seq., Commission
Directive 2003/94/EC the EU Good Manufacturing Practice guideline, Volume 4 for medicinal products
for Human and Veterinary Use, the European Pharmacopoeia, and equivalent thereof, as applicable,
each as amended from time to time.

     1.7 “Change of Control” means, as to Alpharma or Durect, the occurrence of a tender
offer, stock purchase, other stock acquisition, merger, consolidation, recapitalization, reverse
split, sale or transfer of assets or other transaction, or series of transactions, as a result of
which any person, entity or group, other than an Affiliate of Alpharma or Durect, as the case may
be, prior to the occurrence of such event (a) becomes the beneficial owner, directly or indirectly,
of

CONFIDENTIAL

2

 

securities of Alpharma or Durect, as the case may be, representing more than 50% of the
ordinary shares of Alpharma or Durect, as the case may be, or representing more than 50% of the
combined voting power with respect to the election of directors of Alpharma or Durect, as the case
may be, (b) obtains the ability to appoint a majority of the board of directors of Alpharma or
Durect, as the case may be, or (c) obtains the ability to direct the operations or management of
Alpharma or Durect, as the case may be.

     1.8 “Clinical Trial” means an investigation in human subjects and/or patients intended
to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an
investigational product(s), and/or to identify any adverse reactions to an investigational
product(s), and/or to study absorption, distribution, metabolism, and/or excretion of an
investigational product(s) with the objective of ascertaining its safety, activity and/or efficacy.

     1.9 “Collaboration Inventions” means all Know-How (whether or not patentable)
conceived and/or reduced to practice by or for a Party, or any Affiliate, subcontractor, agent, or
sublicensee thereof, or jointly by any of the foregoing, arising out of or in connection with
performing the activities under this Agreement, including the Development Plan. For clarity, and
notwithstanding the foregoing, the definition of “Collaboration Inventions” shall not be construed
to cover Development Data.

     1.10 “CMC” means chemistry, manufacturing and controls.

     1.11 “CMC Data” means CMC data generated with respect to the Product that is
Controlled at any time during the Term of this Agreement by a Party, or any Affiliate,
subcontractor, agent, sublicensee thereof, or jointly by any of the foregoing.

     1.12 “CMO” means a Third Party contract manufacturing organization.

     1.13 “Committee” means any of the Joint Executive Committee (JEC) or the Joint
Development Committee (JDC), and when used in the plural, shall mean all of them or more than one
of them, as the case may be.

     1.14 “Commercialization” or “Commercialize” means the ongoing process and
activities generally engaged in by a company marketing human pharmaceutical therapeutic products to
establish and maintain a presence for such product in a given territory, including

CONFIDENTIAL

3

 

offering for sale, selling, marketing, promoting, distributing, importing and exporting such
product.

     1.15 “Commercially Reasonable Efforts” with respect to any activity means the efforts
and resources that would be used by a specialty pharmaceutical company of comparable size and
resources as Alpharma in the development, registration, Reimbursement authorization, market launch
and/or manufacturing, with regard to a product at a similar stage in its product life taking into
account the following factors to the extent reasonable and relevant: issues of safety and
efficacy, product profile, market potential, difficulty in manufacturing the product, difficulty in
establishing an appropriate clinical protocol for applicable indications, competitive market
conditions, the patent, duration of regulatory exclusivity or other proprietary position of the
product, the regulatory structure involved and the potential profitability and economic return of
the product [**], all as measured by the facts and circumstances at the time such efforts are due.
Where this Agreement requires Alpharma to use Commercially Reasonable Efforts, such efforts and
resources that are used by Alpharma’s Affiliates and sublicensees shall also be attributed to
Alpharma.

     1.16 “Competitive Product” means any formulation containing Bupivacaine, either alone
or in combination with one or more other active ingredients, for transdermal delivery from a patch
for use in the Field, other than the Product.

     1.17 “Control” or “Controlled” means possession by a Party or its Affiliate of
the right to grant to the other Party a license, sublicense or other right to use, of the scope
provided for in this Agreement, to Intellectual Property Rights (including patent rights, Know-How,
trade secrets), data and rights to access or cross-reference regulatory filings without violating
the terms of any Applicable Law, agreement or other arrangement with any Third Party existing at
the time such Party or such Affiliate would be first required hereunder to grant the other Party
such license, sublicense or other right.

     1.18 [**].

     1.19 [**].

     1.20 “Cost” means all internal and external costs, expenses, cost of labor and
materials associated with an activity.

CONFIDENTIAL

4

 

     1.21 “Development Data” means all Preclinical, Non-Clinical and Clinical data and all
CMC Data, including pharmacological, pharmacokinetic and toxicological data generated with respect
to the Product that is Controlled at any time during the Term of this Agreement by a Party, or any
Affiliate, subcontractor, agent, sublicensee thereof, or jointly by any of the foregoing.

     1.22 “Dollars” means U.S. Dollars, the lawful currency of the United States.

     1.23 “Dosage Form Development” means any pharmaceutical development activities for the
Product that are necessary to design or modify a pharmaceutical formulation or dosage form to meet
the desired clinical or commercial product profile, including in vitro studies on solubility,
stability, physical and chemical characteristics, denaturation, particle formation,
crystallization, micronization, excipient/material selection, compounding, mixing, casting,
converting, drying, and similar activities.

     1.24 “Durect Development Costs” shall mean the Costs incurred by Durect in performing
the Durect Development Responsibilities as calculated in accordance with Schedule 1.24.

     1.25 “Durect Trademark” means the trademark rights to the mark ELADURTM and similar
rights under the laws of any Governmental Entity, including all goodwill associated therewith, and
all applications, registrations, extensions and renewals relating thereto.

     1.26 “EMEA” means the European Medicines Agency, and where and if applicable, the
European Commission, the Council of the European Union and the Committee for Medicinal Products for
Human Use or any successors thereto.

     1.27 “EU” shall mean the European Union, including each of the member states as
modified from time to time.

     1.28 [**].

     1.29 [**].

     1.30 [**].

     1.31 [**].

CONFIDENTIAL

5

 

     1.32 “FDA” means the Food and Drug Administration of the United States Department of
Health and Human Services or any successor agency thereof performing similar functions.

     1.33 “FDC Act” means the United States Federal Food, Drug, and Cosmetic Act and any
successor acts thereto, as amended from time to time.

     1.34 “Field” means all pharmaceutical applications (including the treatment of pain)
for human health.

     1.35 “First Commercial Sale” means: (i) with respect to a Jurisdiction, the first sale
for use, consumption or resale of Product by Alpharma or an Affiliate or Sublicensee thereof to a
Third Party in a bona fide arms’-length transaction in such Jurisdiction and (ii) with respect to
the Territory, the First Commercial Sale in any Jurisdiction. A sale to an Affiliate shall not
constitute a First Commercial Sale unless the Affiliate is the end-user of the Product.

     1.36 “GAAP” means generally accepted accounting principles in the United States,
consistently applied by the Party at issue.

     1.37 “Generic Product” means a generic pharmaceutical Bupivacaine transdermal patch
that is approved for the same labeled indication as the Product under an ANDA pursuant to the FDC
Act, Article 10 of the EU Directive 2001/83/EC or other equivalent registration process under the
Applicable Laws of the relevant Jurisdiction in which the Product is cited as the reference listed
drug.

     1.38 “Governmental Entity” means any regional, central, federal, state, provincial or
local court, commission or governmental, regulatory or administrative body, board, bureau, agency,
instrumentality, authority or tribunal or any subdivision thereof.

     1.39 “HSR” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

     1.40 “ICH Guidelines” means the then-current guidelines applicable to pharmaceutical
products adopted by the International Conference on Harmonization.

     1.41 “IND” means an investigational new drug application (together with all subsequent
submissions, supplements and amendments thereto, and any materials, documents or information
referred to or relied upon thereby) filed with a Regulatory Authority in conformance

CONFIDENTIAL

6

 

with applicable laws and regulations, and the equivalent thereof (or other right to commence
Clinical Trials), as applicable, in Jurisdictions outside the United States.

     1.42 “Intellectual Property Rights” means patents, copyrights, trade secrets, database
rights, proprietary know-how and similar rights of any type (excluding trademarks) under the laws
of any Governmental Entity, including all applications, registrations, extensions and renewals
relating to any of the foregoing.

     1.43 “Jurisdiction” means a country within the Territory.

     1.44 “Know-How” means all technical information and other technical subject matter,
proprietary methods, ideas, concepts, formulations, discoveries, inventions, devices, technology,
trade secrets, compositions, designs, formulae, know-how, show-how, specifications, drawings,
techniques, results, processes, methods, procedures and/or designs, whether or not patentable.

     1.45 “Knowledge” means the actual knowledge of a Party’s executive officers.

     1.46 “Manufacturing Technology” means all Know-How Controlled by a Party or any of its
Affiliates that pertains to the manufacture, finishing, or packaging of the Product, including any
analytical methods and other quality control and assurance methods (including all processes,
procedures, and techniques).

     1.47 “MAA” means a “Marketing Authorization Application” or other application for
approval to market the Product in a Jurisdiction in the EU submitted to the Governmental Entity of
such Jurisdiction, including any Marketing Authorization, as amended or supplemented from time to
time.

     1.48 “Marketing Authorization” or “MA” means any registrations or
authorizations issued under Directive 2001/83/EC (as amended by Directive 2004/27) or local
legislation deriving thereof, Council Regulation 726/04 and any amendments or replacements thereof
or any national equivalents in relation to the Product.

     1.49 “Marketing Exclusivity Right” means a marketing or data exclusivity right
conferred as a result of (a) designation as a drug for rare diseases or conditions under Sections
525 et seq. of the FDC Act, (b) an exclusive right to sell under an NDA pursuant to Section
505(j)(5)(F)(ii), (iii) and (iv) or 505(c)(3)(E)(ii), (iii) and (iv) of the FDC Act or any relevant
subsequent legislation, rules or regulations, (c) the exclusive right granted by the FDA upon

CONFIDENTIAL

7

 

completion of pediatric studies requested by the FDA under Section 505A(a) of the FDC Act, (d)
Article 10 of EU Directive 2001/83/EC and/or Article 3(3) of EU Regulation 726/2004/EC or (e) EU
Regulations 141/2000/EC and/or 847/2000/E, as applicable, or any equivalent or similar rights in
the Territory or Jurisdiction, successor legislations of any of the foregoing or subsequent
legislation that has the effect of extending marketing or data exclusivity right to a
pharmaceutical product.

     1.50 “NDA” means a “New Drug Application,” or other application for Regulatory
Approval to market a product in the U.S. submitted to the FDA as amended or supplemented from time
to time.

     1.51 “Non-Clinical” when used with respect to studies or data refers to safety,
toxicology and other studies undertaken in non-human animals in support of Clinical Trials or
otherwise required for Regulatory Approval.

     1.52 “Net Sales” means the gross amount invoiced by Alpharma, and/or its Affiliates
and Sublicensees for sale or other commercial disposition of the Product (in its final, finished
form for use by the end-user) to an unrelated Third Party in arms’-length transactions, less the
following deductions which are actually incurred, allowed, accrued or specifically allocated in
their normal and customary amounts: (i) credits, price adjustments (including co-pay reduction
programs) or allowances for damaged products, returns or rejections of Product; (ii) trade, cash
and quantity discounts, allowances and credits (including with respect to marketing programs such
as coupon programs); (iii) chargeback payments, fees and rebates (or the equivalent thereof)
granted to group purchasing organizations, managed health care organizations, wholesalers, pharmacy
benefit management (PBM) or other similar organizations or to federal, state/provincial, local and
other governments, including their agencies, or to trade customers; (iv) any invoiced freight,
postage, shipping, insurance and other transportation charges; (v) reasonable provisions for
allowance for uncollectible amounts; and (vi) sales, value-added, and excise taxes, tariffs and
duties, and other taxes directly related to the sale (but not including taxes assessed against the
income derived from such sale).

     For clarity, Net Sales shall be determined in accordance with GAAP and a sale or transfer by
Alpharma to its Affiliates and/or Sublicensees for resale by such Affiliate and/or Sublicensee
shall not be considered a sale for the purpose of this provision but the resale by such Affiliate

CONFIDENTIAL

8

 

and/or Sublicensee to a Third Party shall be a sale for such purposes. Transfer for Preclinical
trials and Clinical Trials, testing or market research or promotional purposes shall not be a sale
for the purpose of calculating Net Sales.

     1.53 “Orphan Indication” means a disease or condition which qualifies as a “rare
disease or condition” under the Orphan Drug Act (21 U.S.C. 360aa et seq.) and regulations relating
thereto (21 CFR Part 316), including amendments and successor laws and regulations thereto.

     1.54 “PHN” means persistent pain associated with post-herpetic neuralgia.

     1.55 “Party” means Durect or Alpharma, as the case may be, and, when used in the
plural, shall mean Durect and Alpharma.

     1.56 “Patent” and “Patents” mean issued patents and patent applications,
including any and all provisionals, continuations, divisionals, continuation-in-part applications,
foreign counterparts, substitutions, reissues, renewals, re-examinations, supplementary protection
certificates, patent term extensions, adjustments or restoration rights, registrations,
confirmations, successor protective rights or subsequently issued protective rights of similar
nature of any of the above.

     1.57 “Person” means an individual or a corporation, partnership, association, trust,
or any other entity or organization, including a government or political subdivision or an agency
or instrumentality thereof.

     1.58 “Preclinical” when used with respect to studies or data refers to preliminary
pharmacological studies undertaken in non-human animals, but not necessarily for purposes of
submission in support of Regulatory Approval.

     1.59 “Pricing” or “Pricing Approval” means any approval or authorization of a
Governmental Entity, establishing a pricing scheme for Product in a Jurisdiction.

     1.60 “Product” means the product under development by Durect currently known as
ELADURTM, consisting of a transdermal patch containing Bupivacaine as the sole active pharmaceutical
ingredient for use in the Field which incorporates Product Know-How and/or is covered by Product
Patent Rights, including all dosage strengths thereof, as described in Schedule 1.60 hereto.
Product shall include any improvements, reformulations and line

CONFIDENTIAL

9

 

extensions thereof, in each case consisting of a transdermal patch containing Bupivacaine as
the sole active pharmaceutical ingredient for use in the Field which incorporates Product Know-How
and/or is covered by Product Patent Rights (hereinafter “Line Extension(s)”).

     1.61 “Product Know-How” means Know-How related to the Product that is (a) Controlled
by Durect or any of its Affiliates during the Term of this Agreement and (b) useful for a Party, or
its Affiliates and/or licensees to develop, make, have made, use, Commercialize and/or register the
Product.

     1.62 “Product Patents Rights” means (i) those Patents in the Territory Controlled by
Durect or any of its Affiliates during the Term which relate to the Product, excluding the [**] and
(ii) those Patents in the Territory Controlled by Durect or any of its Affiliates during the Term
which cover Product Collaboration Inventions. Schedule 1.62 set forth a list of Product Patent
Rights, as such list may be updated from time to time.

     1.63 [**].

     1.64 “Regulatory Approval” means, with respect to one or more Jurisdictions, final
approval of the Regulatory Approval Application (including, with respect to any Jurisdiction(s)
other than the U.S., any Pricing Approvals and/or Reimbursement Approvals that Alpharma reasonably
determines, consistent with the exercise of Commercially Reasonable Efforts, are commercially
necessary prior to commercial sale of the Product in such Jurisdiction(s)) for the Product filed in
such Jurisdiction(s), including an approved NDA in the U.S., Marketing Authorization in the EU, or
equivalent local final approvals in Jurisdictions.

     1.65 “Regulatory Approval Application” means a new drug application, health
registration, marketing authorization application, common technical document, regulatory
submission, notice of compliance or equivalent application (excluding local and general business
licenses and permits) required to be approved before commercial sale or use of the Product as a
pharmaceutical or medicinal product in a Jurisdiction (including, with respect to any Jurisdiction
other than the U.S., any Pricing Approvals and/or Reimbursement Approvals that Alpharma reasonably
determines, consistent with the exercise of Commercially Reasonable Efforts, are commercially
necessary prior to commercial sale of the Product in such Jurisdiction), together with all
subsequent submissions, supplements and amendments thereto, including an NDA in the U.S., MAA in
the EU or local approvals in the Jurisdictions as applicable.

CONFIDENTIAL

10

 

     1.66 “Regulatory Authority” means the FDA, EMEA and any health regulatory authorities
in the Territory or Jurisdiction that hold responsibility for the regulation of and/or the
Reimbursement of medicinal products intended for human use.

     1.67 “Regulatory Documentation” means all submissions to Regulatory Authorities and
other Governmental Entities, including for Clinical Trials, tests, and biostudies, relating to the
Product, including all INDs and NDAs, as well as all correspondence with Governmental Entities
(registration and licenses, Pricing and Reimbursement correspondence, regulatory drug lists,
advertising and promotion documents), adverse event files, complaint files, manufacturing records
and inspection reports.

     1.68 “Reimbursement” or “Reimbursement Approval” means the official decision
by the relevant Governmental Entity in any Jurisdiction responsible for establishing a
reimbursement scheme to cover the costs related to the treatment of patients with the Product.

     1.69 “Royalty Term” means, with respect to the Product in each Jurisdiction of the
Territory on a Jurisdiction-by-Jurisdiction basis, the period of time commencing on the First
Commercial Sale of the Product in such Jurisdiction and ending on the later of: (a) fifteen (15)
years from the date of the First Commercial Sale of the Product in such Jurisdiction and (b) the
end of the Patent Royalty Term in such Jurisdiction.

     1.70 [**].

     1.71 “Specifications” means the specifications for the Product, considering the
applicable regulatory requirements in the Territory, as may be amended from time to time.

     1.72 “Sublicense” means the sublicense by Alpharma of Commercialization rights to the
Product to any Third Party in the Territory such that the Third Party has the right to record sales
for its own account in lieu of Alpharma (such Third Party grantee shall be deemed a
“Sublicensee”).

     1.73 “Sublicense Fees” means any upfront payments, milestone payments and other
license payments (including the fair market value of debt or equity securities or other
consideration) received by Alpharma or any Affiliate thereof as consideration for a Sublicense.
For clarity, and notwithstanding the foregoing, Sublicense Fees shall not include any royalties
based on Product sales received by Alpharma or its Affiliates, any bona fide research and

CONFIDENTIAL

11

 

development funding paid to Alpharma and its Affiliates for research and development
activities performed by Alpharma or any of its Affiliates with respect to the Product, or the fair
market value purchase price paid to Alpharma or any of its Affiliates by a Sublicensee for the
purchase of any debt or equity securities of Alpharma or any of its Affiliates.

     1.74 “Subterritory” means each one of the following:

	 	 	 	Subterritory A — The United States of America (including territories and
protectorates thereof)
	 
	 	 	 	Subterritory B — EU
	 
	 	 	 	Subterritory C — Japan
	 
	 	 	 	Subterritory D — All Jurisdictions of the Territory excluding Jurisdictions
in Subterritories A, B and C

     1.75 “Terminated Countries” means those Jurisdictions in the Territory for which
Alpharma’s rights to develop and Commercialize the Product have been terminated in accordance with
Sections 4.2(c) or 4.3(d).

     1.76 “Territory” means all the countries in the world excluding Terminated Countries,
if any.

     1.77 “Third Party” means any Person who or which is neither a Party nor an Affiliate
of a Party.

     1.78 [**].

     1.79 “Valid Claim” means, with respect to Product in a particular Jurisdiction, any
claim of a Patent that either:

          (a) with respect to a granted and unexpired Patent in such Jurisdiction, that (i) has not
been held permanently revoked, unenforceable or invalid by a decision of a court or other
Governmental Entity of competent jurisdiction, which decision is unappealable or unappealed within
the time allowed for appeal, and (ii) has not been abandoned, disclaimed, denied or admitted to be
invalid or unenforceable through reissue or disclaimer or otherwise; or

          (b) with respect to a pending Patent application, that was filed and is being prosecuted in
good faith and has not been abandoned or finally disallowed without the possibility of appeal or
re-filing of the application; provided, however, that such claim is not

CONFIDENTIAL

12

 

pending more than [**] years after the filing of the earliest patent application from which
such pending claim claims priority.

     1.80 Other Definitions.

     Each of the following terms is defined in the Section set forth opposite such term below:

     “AAA” – Section 14.12(b)

     “Adverse Event” – Section 4.9

     “Agreement” – Preamble

     “Alliance Manager” –Section 2.6.

     “Alpharma”—Preamble

     [**]

     “Alpharma Post-Registration Study”—Section 5.2

     “Alpharma Related Party”—Section 12.1

     [**]

     “Annual Net Sales Period” – Section 6.2(a)

     “Audited Party” – Section 7.5

     “Auditing Party” – Section 7.5

     “Confidential Information” – Section 10.4

     “CRO” – Section 13.7(c)

     “Damages” – Section 12.1

     [**]

     “Designated Executives” – Section 2.1(d)

     “Development Plan” – Section 4.2

     “Development Plan Budget” – Section 4.2

     “Development Program” – Section 4.1

     “Dispute” – Section 14.12(b)

     “Durect” – Preamble

     [**]

     “Durect Development Responsibilities” – Section 4.6

     “Durect Related Party” – Section 12.2

     “Effective Date” –Section 13.2(a)

     “Execution Date” – Preamble

CONFIDENTIAL

13

 

     “First Major Market Jurisdiction”—Section 4.3(b)

     “First Refusal Notice”—Section 3.6

     “Force Majeure”– Section 14.14

     “Indemnified Party” –Section 12.4

     “Indemnifying Party” –Section 12.4

     “Joint Development Committee” or “JDC”– Section 2.2(a)

     “Joint Executive Committee” or “JEC” — Section 2.1(a)

     “Joint Invention”—Section 9.1(d)

     “Joint Patent Rights”—Section 9.2(b)

     “Know-How Royalty Term” — Section 6.2(b)

     “Line Extensions”—Section 1.60

     “Major Market Jurisdiction”—Section 4.3

     “Negotiation Period”—Section 3.6

     “One-Time Payment”—Section 6.1

     “Patent Litigation Losses”—Section 9.6(c)

     “Patent Royalty Term” —Section 6.2(a)

     “Patent Term Extensions” —Section 9.7

     “Product Collaboration Inventions”—Section 9.1(b)

     “Product Material”—Section 13.7(b)

     “Product Trademarks”—Section 3.5(a)

     “Resolution Period” – Section 2.1(d)

     “Royalties” –Section 6.2

     “Rules” – Section 14.12(b)

     “Second Major Market Jurisdiction”—Section 4.3(b)

     “Serious Adverse Drug Experience”—Section 13.3(b)

     “Sublicensee” – Section 1.72

     “Technology Transfer Plan”—Section 8.2

     “Term”—Section 13.1.

     “Third Party License Fees”—Section 9.6(e)

     1.81 Interpretation

CONFIDENTIAL

14

 

          (a) Whenever any provision of this Agreement uses the term “including” (or “includes”), such
term shall be deemed to mean “including without limitation” and “including but not limited to” (or
“includes without limitations” and “includes but is not limited to”) regardless of whether the
words “without limitation” or “but not limited to” actually follow the term “including” (or
“includes”);

          (b) “Herein”, “hereby”, “hereunder”, “hereof” and other equivalent words shall refer to this
Agreement in its entirety and not solely to the particular portion of this Agreement in which any
such word is used;

          (c) All definitions set forth herein shall be deemed applicable whether the words defined are
used herein in the singular or the plural;

          (d) Wherever used herein, any pronoun or pronouns shall be deemed to include both the
singular and plural and to cover all genders;

          (e) The recitals set forth at the start of this Agreement, along with the Exhibits and
Schedules to this Agreement, and the terms and conditions incorporated in such recital, Exhibits
and Schedules shall be deemed integral parts of this Agreement and all references in this
Agreement to this Agreement shall encompass such recitals, Exhibits and Schedules and the terms
and conditions incorporated in such recitals, Exhibits and Schedules, provided, that in the event
of any conflict between the terms and conditions of this Agreement and any terms and conditions
set forth in the Exhibits and Schedules, the terms of this Agreement shall control;

          (f) In the event of any conflict between the terms and conditions of this Agreement and any
terms and conditions that may be set forth on any order, invoice, verbal agreement or otherwise,
the terms and conditions of this Agreement shall govern;

          (g) The Agreement shall be construed as if both Parties drafted it jointly, and shall not be
construed against either Party as principal drafter;

          (h) Unless otherwise provided, all references to Sections, Schedules and Exhibits in this
Agreement are to Sections, Schedules and Exhibits of and to this Agreement;

          (i) All references to days, months, quarters or years are references to calendar days,
calendar months, calendar quarters or calendar years unless otherwise expressly

CONFIDENTIAL

15

 

provided; references to a “business day” herein shall mean a day when both Alpharma and
Durect corporate headquarters are open during regular business hours for the conduct of normal
business operations.

          (j) Any reference to any federal, national, state, local or foreign statute or law shall be
deemed to also refer to all rules and regulations promulgated thereunder, unless the context
requires otherwise;

          (k) Any requirements of notice or notification by one Party to another shall be construed to
mean written notice in accordance with Section 14.5; and

          (l) Wherever used, the word “shall” and the word “will” are each understood to be imperative
or mandatory in nature and are interchangeable with one another.

2. GOVERNANCE.

     2.1 Joint Executive Committee.

          (a) Members; Officers. The Parties hereby establish a joint executive committee (the
“Joint Executive Committee” or “JEC”), which shall consist of up to [**] members
with an equal number of members nominated by each of Durect and Alpharma. The initial members of
the JEC are set forth on Schedule 2.1, as may be amended by the designating Party from time to
time. Representatives of the JEC shall be employees of the respective Party or its Affiliates.
Each of Durect and Alpharma may replace any or all of its representatives on the JEC at any time
upon written notice to the other Party. Any member of the JEC may designate a substitute with due
authority to temporarily attend and perform the functions of that member at any meeting of the
JEC. Durect and Alpharma each may, in its discretion, invite non-member representatives that are
employees of such Party (or such Party’s Affiliates) and, with the other Party’s consent,
consultants to attend meetings of the JEC. The JEC shall be chaired by a representative of
Alpharma (or its Affiliates), as such representative may be changed by Alpharma at any time. The
chairperson shall appoint a secretary of the JEC, and such secretary shall serve for such term as
designated by the chairperson. The initial chairperson is designated on Schedule 2.1.

CONFIDENTIAL

16

 

          (b) Responsibilities. The JEC shall perform the following functions:

          (i) manage and oversee the interactions and performance of the Parties pursuant to the
terms of this Agreement (including the development and Regulatory Approval process of the
Product in the Territory);

          (ii) review and approve any modifications or amendments to the Development Plan and
Development Plan Budget;

          (iii) review and advise Alpharma regarding final label indications for the Product in
Subterritory A and Major Market Jurisdictions;

          (iv) at each meeting, as applicable, review the Product development status and
expenditures with the activities, timelines and budget set forth in the Development Plan as
well as discuss any deviations from the Development Plan;

          (v) recommend further development activities after Regulatory Approval of the Product
in each Jurisdiction, including Phase 4 studies;

          (vi) review and evaluate the progress of the JDC;

          (vii) in accordance with the procedures established in Section 2.1(d), resolve
disputes, disagreements and deadlocks unresolved by the JDC;

          (viii) review and advise Alpharma regarding Alpharma’s publication strategy for
scientific publications relating to the Product other than medical education and marketing
publications;

          (ix) consider and approve the development of any Line Extensions to the Product in the
Territory;

          (x) establish trademark usage and quality standards in accordance with Section 9.8; and

          (xi) have such other responsibilities as may be assigned to the JEC pursuant to this
Agreement or as may be mutually agreed upon by the Parties from time to time.

          (c) Meetings. The JEC shall meet in person, by video teleconference or by telephone
initially at least [**] prior to the first Regulatory Approval of a Product in

CONFIDENTIAL

17

 

Subterritory A and thereafter at least [**], and more frequently as Durect and Alpharma deem
appropriate or as required to resolve disputes, disagreements or deadlocks in the JDC, on such
dates, and at such places and times, as the Parties shall agree. From time to time, each Party
may request a JEC meeting upon notice to the other Party specifying the subject matters to be
discussed, and the Parties shall convene such JEC meeting within [**] of the date of the notice.
Meetings of the JEC that are held in person shall alternate between the offices of Durect and
Alpharma (or the offices of their Affiliates designated by such Parties), or such other place as
the Parties may agree. The members of the JEC also may convene or be polled or consulted from
time to time by means of telecommunications, video conferences, electronic mail or correspondence,
as deemed necessary or appropriate.

          (d) Decision-making. The JEC may make decisions with respect to any subject matter
that is subject to the JEC’s decision-making authority and functions as set forth in Section
2.1(b). All decisions of the JEC shall be made by unanimous vote or written consent, with Durect
and Alpharma each having, collectively, one vote in all decisions. The JEC shall use good faith
and reasonable efforts to resolve the matters within its roles and functions or otherwise referred
to it. With respect to all matters that are subject to the JEC’s decision-making authority, if
the JEC cannot reach consensus within [**] after it has met and attempted to reach such consensus,
including discussions between the Alliance Managers, the matter shall be referred on the [**] to
the designated executive officers (“Designated Executives”) of Alpharma and Durect who
shall meet as soon as practicable, but no later than [**] after such referral, to attempt in good
faith to resolve the dispute. If the dispute related to the matter is not resolved by the
Designated Executives by mutual agreement within [**] after a meeting to discuss the dispute (such
[**] period after the meeting of the Designated Executives shall be referred to as the
“Resolution Period”), [**].

     2.2 Joint Development Committee.

          (a) Members; Officers. The Parties hereby establish a joint development committee
(the “Joint Development Committee” or “JDC”), which shall consist of up to [**]
members with an equal number of members nominated by each of Durect and Alpharma, one of whom shall
be designated by Alpharma as chairman. The initial representatives on the JDC are set forth on
Schedule 2.2, as may be amended by the designating Party from time to time. Each

CONFIDENTIAL

18

 

of Durect and Alpharma may replace any or all of its representatives on the JDC at any time
upon notice to the other Party. Such representatives shall be employees of each such Party or its
Affiliates, and those representatives of each such Party shall, individually or collectively, have
expertise in pharmaceutical drug development, regulatory matters, manufacturing, Clinical Trials,
Non-Clinical studies and/or other expertise to the extent relevant. Any member of the JDC may
designate a substitute with due authority to temporarily attend and perform the functions of that
member at any meeting of the JDC. Durect and Alpharma each may invite non-member representatives
that are employees of Alpharma or Durect (or their Affiliates) or external consultants of a Party
to attend meetings of the JDC, provided that such external consultants have signed customary
confidentiality agreements. The secretary of the JDC shall initially be designated by Alpharma and
thereafter alternate between a representative of Durect and a representative of Alpharma.

          (b) Responsibilities. The JDC shall perform the following functions:

          (i) review and monitor the progress of the Development Program in accordance with the
Development Plan;

          (ii) monitor the progress of regulatory filings and submissions for the Product in the
Territory;

          (iii) facilitate the exchange of information and coordinate between the Parties as
necessary or useful for development of the Product in the Territory;

          (iv) review a comparison of actual development costs of the Development Program to the
Development Plan Budget for the year-to-date on a quarterly basis, such comparison to be as
current as practicable as of the date of the meeting at which the review occurs, which
comparison will be used as a basis for evaluating proposed changes to the Development Plan
and the Development Plan Budget; and

          (v) have such other responsibilities as may be assigned to the JDC pursuant to this
Agreement or as may be mutually agreed upon by the Parties from time to time.

CONFIDENTIAL

19

 

          (c) Meetings. The JDC shall meet in person, by video teleconference or by telephone
initially at least [**], and more or less frequently as Durect and Alpharma deem appropriate or as
reasonably requested by either such Party, on such dates, and at such places and times, as such
Parties shall agree. From time to time, each Party may request a JDC meeting upon written notice
to the other Party specifying the subject matters to be discussed, and the Parties shall convene
such JDC meeting within [**] of the date of the notice. Meetings of the JDC that are held in
person shall alternate between the offices of Durect and Alpharma, or such other place as such
Parties may agree. The members of the JDC also may convene or be polled or consulted from time to
time by means of telecommunications, video conferences, electronic mail or correspondence, as
deemed necessary or appropriate.

          (d) Decision-making. The JDC may make decisions with respect to any subject matter
that is subject to the JDC’s decision-making authority and functions as set forth in Section
2.2(b). All decisions of the JDC shall be made by unanimous vote or written consent, with Durect
and Alpharma each having, collectively, one vote in all decisions. If, with respect to any matter
that is subject to the JDC’s decision-making authority, after all reasonable efforts to reach
consensus have been exhausted, including discussions between the Alliance Managers, the JDC cannot
reach consensus within [**] after it has first met and attempted to reach such consensus, the
matter shall be referred on the [**] to the JEC for resolution. For all purposes under this
Agreement, any decision made pursuant to this Section 2.2(d) shall be deemed to be the decision of
the JDC. [**].

     2.3 Minutes of JEC and JDC Meetings.

          (a) Definitive minutes of all JEC and JDC meetings shall be finalized no later than [**]
after the meeting to which the minutes pertain, as follows:

          (i) Within [**] after a JEC or a JDC meeting, the secretary of such JEC or JDC shall
prepare and distribute to all members of such JEC or JDC draft minutes of the meeting. Such
minutes shall provide a list of any actions, decisions or determinations approved by such
JEC or JDC and a list of any issues yet to be resolved (listing responsible persons and
target completion dates), either within such JEC or JDC, or through the relevant escalation
process.

CONFIDENTIAL

20

 

          (ii) The secretary of such JEC or JDC shall have [**] after distribution of the draft
minutes to discuss each JEC or JDC member’s comments and finalize the minutes. The
secretary and chairperson(s) of such JEC and JDC shall each sign and date the final minutes.
The signature of such chairperson(s) and secretary upon the final minutes shall indicate
each Party’s assent to the minutes.

          (b) If at any time during the preparation and finalization of JEC or JDC meeting minutes, the
JEC and JDC members do not agree on any issue with respect to the minutes, such issue shall be
resolved as provided in Section 2.1(d) or 2.2(d), as the case may be. The decision resulting from
the foregoing process shall be recorded by the secretary in amended finalized minutes for said
meeting. All other issues in the minutes that are not subject to the foregoing process shall be
finalized within the [**] period as provided in Section 2.3(a).

     2.4 Duration of Committees. The JEC shall exist until the termination of this
Agreement, unless [**], and the Parties shall thereafter agree to alternative ways to cover the
responsibilities and duties of the JEC. The JDC shall exist until [**], and the Parties shall
thereafter discuss alternative ways to cover the responsibilities and duties of the JDC.

     2.5 Expenses. Each Party shall be responsible for all travel and related Costs for its
members and other representatives to attend meetings of, and otherwise participate on, a Committee.

     2.6 Alliance Managers. Each of Durect and Alpharma shall appoint one employee
representative who possesses a general understanding of Clinical, regulatory, manufacturing and
marketing issues to act as its respective alliance manager for this relationship (each, an
“Alliance Manager”). The initial Alliance Managers are set forth on Schedule 2.6, as
amended by the designating Party from time to time. Each of Durect and Alpharma may replace its
respective Alliance Manager at any time upon written notice to the other. Any Alliance Manager may
designate a substitute with due authority to temporarily perform the functions of that Alliance
Manager. Each Alliance Manager shall be charged with creating and maintaining a collaborative work
environment within and among the Committees. Each Alliance Manager will also be responsible for:

CONFIDENTIAL

21

 

          (a) providing a single point of communication for seeking consensus both internally within
the respective Party’s organizations and between the Parties regarding business, contractual and
strategic issues;

          (b) identifying and raising cross-Party and/or cross-functions disputes to the appropriate
Committee in a timely manner; and

          (c) planning and coordinating internal and external communications.

     The Alliance Managers shall be entitled to attend meetings of any of the Committees, but shall
not have, or be deemed to have, any rights or responsibilities of a member of any Committee. Each
Alliance Manager may bring any matter to the attention of any Committee where such Alliance Manager
reasonably believes that such matter requires such attention.

     2.7 Scope of Committees. Alpharma and Durect have chartered the Committees with a
belief that vigorous interaction and cooperation between the Parties are essential for the success
of the Product. For the JEC and JDC, each Party shall use all reasonable efforts to reach
consensus decisions at the JEC or JDC level respectively. Nothing in this Section 2, and no
decision made by the JEC or JDC under Sections 2.1(d) or 2.2 (d) shall be deemed to modify or
supersede any express term or condition set forth in this Agreement, nor any decision or
decision-making authority expressly provided to a Party in this Agreement. For clarity, no
Committee shall have the authority to make any determination that any Party is in breach of this
Agreement.

3. GRANT OF RIGHTS.

     3.1 Rights Granted to Alpharma. On the terms and subject to the conditions of this
Agreement, Durect hereby grants to Alpharma:

          (a) the exclusive right and license to make, have made, use, offer for sale, sell and import
the Product in the Territory, including the right to record sales for its own account;

          (b) in each case, solely for use in the Field and Territory and in connection with Alpharma’s
development and Commercialization of the Product and to otherwise exercise Alpharma’s rights and
perform its obligations under this Agreement:

          (i) an exclusive license under the Product Patents Rights and Product Know-How;

CONFIDENTIAL

22

 

          (ii) [**];

          (iii) [**]; and

          (iv) subject to the terms of the [**] Agreement, an exclusive sublicense under Durect’s
license to the [**] Intellectual Property; and

          (c) an exclusive license and right of cross-reference to all Development Data Controlled by
Durect in existence as of the Effective Date solely to exercise its rights and licenses under this
Agreement with respect to the Product.

     3.2 Sublicense Rights. Alpharma shall have the right, [**] to delegate rights and
obligations hereunder to an Affiliate and to appoint Affiliates to Commercialize the Product in the
Territory. Furthermore, Alpharma shall have the right to appoint any Third Party designee(s) to
develop, manufacture and Commercialize the Product in the Territory alone or in combination with
Alpharma or its Affiliates and/or to sublicense the rights granted to it under Section 3.1;
provided that in the event of any sublicense or delegation of rights by Alpharma
hereunder, such sublicense or delegation shall be subject to the terms and conditions of this
Agreement that, by their terms, are applicable to such sublicense or delegation, and the sublicense
or delegation by Alpharma hereunder shall not relieve Alpharma of its obligations under the
Agreement.

     3.3 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or
pursuant to this Agreement, including amendments hereto, by each Party to the other Party are, for
all purposes of 11 U.S.C. Section 365(n), licenses of rights to intellectual property as defined in
Title 11. Each Party may elect to retain and may fully exercise all of its rights and elections
under 11 U.S.C. Section 365(n).

    3.4 Exclusivity. (a) (a) During the Term of this Agreement, Durect and its Affiliates
shall not develop or manufacture (except in performance of this Agreement) nor Commercialize, and
shall not grant any rights or licenses to any Third Party to develop or manufacture (except
in performance of this Agreement) or Commercialize the Product in the Territory.

     (b) During the Term of this Agreement, neither Party nor its Affiliates shall directly or
indirectly develop or Commercialize a Competitive Product in the Territory, nor sponsor, license
or contract with a Third Party to do any of the foregoing acts. Notwithstanding the foregoing,
however, but subject to Sections 3.1 and 3.2, however, in the

CONFIDENTIAL

23

 

event of a Change of Control of a
Party, the restrictions contained in this Section 3.4(b) shall[**]. In the event that a Party or
one of its Affiliates obtains “control” (as defined in Section 1.2) [**] such Party shall, [**]
such control.

          3.5 Trademarks; Logos.

          (a) Product Trademarks. Alpharma shall have the right to select the Product name and
all trademarks used in connection with the marketing, promotion and Commercialization of the
Product including special promotional or advertising taglines used in connection with the
marketing of the Product, in each case in the Territory (all such trademarks specific to the
Product, with exception of the Durect Trademark, including all goodwill associated therewith, and
all applications, registrations, extensions and renewals relating thereto, shall be referred to as
“Product Trademarks”). During the Term of the Agreement, Alpharma shall be the exclusive
owner of the Product Trademarks and all goodwill associated therewith, and shall use Commercially
Reasonable Efforts to register and maintain, at its Cost, such Product Trademarks as shall be used
for the Commercialization of the Product in the Territory.

          (b) License to Durect Trademark. Subject to the provisions of this Agreement and for
the Term hereof, Durect hereby grants to Alpharma an exclusive license to use the Durect Trademark
in the Territory solely in connection with the Commercialization of Product in the Territory.
Alpharma agrees that all use of the Durect Trademark by Alpharma shall inure to the benefit of and
be on behalf of Durect. Alpharma agrees that it will not challenge the title or ownership of
Durect in the Durect Trademark, or attack or contest the validity of such trademark.

          (c) Durect Rights. To the extent permitted by Applicable Laws, at Durect’s election,
the labels and packaging of all Product to be marketed, distributed or sold in any
Jurisdiction shall include text identifying Durect as the licensor of the Product and a
Durect trademark (other than ELADURTM) selected by Durect to be placed in a size and location
determined in the reasonable, good faith discretion of Alpharma, provided that such mark: (i) is
used in a consistent and noticeable manner sufficient to constitute trademark usage under
Applicable Law, (ii) is clearly identified as a trademark (i.e., through the use of a “®”, “TM” or
other appropriate identifier) and (iii) is not used as combination marks with other marks or

CONFIDENTIAL

24

 

trademarks. Furthermore, Product labels and packaging shall bear appropriate patent markings and
notices as may be applicable.

          3.6 Right of [**] Regarding [**]. Commencing at any time upon [**]
establishment of a development program for a [**], if any, if [**] desires to seek a Third Party to
collaborate in the development and/or Commercialization of such [**] or if [**] elects to
Commercialize such [**], it shall provide written notice thereof (“First Refusal Notice”)
to [**] and provide information reasonably requested by [**] regarding such [**]. Upon receipt of
a First Refusal Notice, [**] shall have [**] to (i) notify [**] in writing if it desires to
participate with [**] in the further development and/or Commercialization of the [**] or (ii)
decline to bid. If [**] does not respond in writing to the First Refusal Notice or notifies [**]
that it declines to bid within such [**] period, then it shall no longer have any rights with
respect to the [**]. If [**] provides [**] with timely notice of its interest in participating in
the development and Commercialization of such [**], then the Parties shall attempt in good faith to
negotiate the terms of an agreement for [**] to participate with [**] in the development or
Commercialization of the [**] for a period of [**] (which may be extended upon written agreement of
the Parties) (“Negotiation Period”). If, despite such good faith negotiations, [**] are
unable to enter into a definitive agreement during such Negotiation Period, then [**] will
thereafter be free to develop or Commercialize such [**] itself or enter into agreement(s) with
Third Parties for the development and Commercialization of such [**]; provided that
if thereafter [**] intends to license Commercialization rights to such [**] to a Third Party more
than [**] after the end of the last Negotiation Period with respect to such [**] or intends to
license Commercialization rights to such [**] to a Third Party on terms and conditions more
favorable to the Third Party when all such terms and conditions are taken in the aggregate than
those last offered to [**] shall first re-offer such opportunity to [**] by delivering a new First
Refusal Notice to [**] and provide to [**] any updated information reasonably requested by [**]
regarding such [**], in which case the second, third, fourth and
fifth sentence of this Section 3.6 shall apply to such new First Refusal Notice.
Notwithstanding anything herein to the contrary in this Section 3.6, however: (a) [**] shall have
no further rights to any [**] if the Parties have not entered into a definitive agreement after
[**] has been offered such [**] in accordance with the terms hereof and after the elapse of [**]
full Negotiation Periods, provided the last offer was made to [**] after such [**] had completed
[**].

CONFIDENTIAL

25

 

4. DEVELOPMENT AND REGULATORY.

     4.1 Development Generally. Commencing upon the Effective Date and subject to Section
4 and other terms of this Agreement, as between Durect and Alpharma, Alpharma shall be responsible,
at its sole Cost, for development of and procuring Regulatory Approval for the Product in the
Territory (all such activities the “Development Program”).

     4.2 U.S. Development.

          (a) Development Plan. As of the Effective Date, the Parties have agreed upon a
development plan (the “Development Plan”) covering the activities necessary for developing
the Product through Regulatory Approval in Subterritory A, including a budget (the
“Development Plan Budget”), activities related to CMC development, Clinical and
Non-Clinical development, Regulatory Approval strategy, capital expenses that are specific to the
Product, activities associated with manufacturing of Product for use in Clinical Trials, process
development, scale-up for providing clinical supplies, and technology transfer (including process
development, scale up and validation activities) as needed to establish commercial scale
manufacturing of the Product for Subterritory A, and other key elements reasonably necessary for
the Parties to fulfill their development responsibilities to each other under the terms of the
Agreement. After the Effective Date, Alpharma shall thereafter update the Development Plan in
accordance with Alpharma’s normal planning cycle, but no less frequently than [**] a year, and
provide a copy thereof to the JEC for review and approval. In the event that the JEC does not
unanimously approve any such update, then such matter shall be resolved in accordance with Section
2.1(d).

          (b) Trials and Regulatory. Pursuant to the Development Plan and subject to this
Section 4 and other terms of this Agreement, Alpharma shall use Commercially Reasonable Efforts to
conduct such Preclinical and Non-Clinical trials and Clinical Trials, at its own Cost, as
necessary to seek and maintain Regulatory Approval of the Product in Subterritory A.
Alpharma shall also use Commercially Reasonable Efforts to obtain Regulatory Approvals for
the Product in Subterritory A, including compiling, submitting and prosecuting all necessary data,
documents and Regulatory Approval Applications (including labeling), in a format acceptable to the
applicable Regulatory Authorities in Subterritory A. If and when any Regulatory Approval is
secured anywhere in Subterritory A, Alpharma shall thereafter use

CONFIDENTIAL

26

 

Commercially Reasonable Efforts
to maintain such Regulatory Approval and pay all user fees and other costs required to maintain
such Regulatory Approval.

          (c) Development Diligence. Alpharma shall use Commercially Reasonable Efforts to
develop the Product through Regulatory Approval in Subterritory A at its sole Cost. Without
limiting the foregoing, Alpharma will use its Commercially Reasonable Efforts to perform the
activities and to meet the timeline in the Development Plan. If, at any time, Alpharma materially
defaults on any of its development obligations with respect to Subterritory A set forth in Section
4 and fails to cure such default within [**] after receipt of written notice of termination from
Durect, Durect shall have the right to terminate Alpharma’s rights with respect to Subterritory A;
provided, however, if the failure is not reasonably capable of being cured within
the [**] cure period by Alpharma and Alpharma is making a good faith effort to cure such failure,
Durect may not terminate Alpharma’s rights in Subterritory A; provided further,
however, that Durect may terminate Alpharma’s rights in Subterritory A if such failure is
not cured within [**] of Durect’s original notice of termination. In the event Durect terminates
Alpharma’s rights with respect to Subterritory A hereunder: (i) Subterritory A shall thereafter be
deemed a Terminated Country and no longer be included in the Territory, and (ii) Durect shall have
the rights set forth in Section 13.7 with respect to Subterritory A. The foregoing termination
rights of Durect shall be Durect’s sole and exclusive remedy and Alpharma’s sole and exclusive
liability for any failure by Alpharma to develop and Commercialize the Product in Subterritory A.

          4.3 Development and Commercialization Diligence Outside the U.S.

          (a) Not later than [**] after the Effective Date, the Parties will jointly begin an
assessment of the market opportunity for the Product for Subterritories B, C and D and develop
criteria for determining which such Jurisdictions present significant commercial potential for the
Product and are subject to the obligations of this Section 4.3. Not later than [**] after the
Effective Date, the Parties will complete such assessment and the development of such
criteria, and identify each Jurisdiction outside of the U.S. in which the development and
Commercialization of Products by Alpharma shall be subject to the obligations of this Section 4.3
(each such country, a “Major Market Jurisdiction”). Thereafter, the Parties shall review
such designations annually and determine whether previously designated countries should

CONFIDENTIAL

27

 

remain or
cease to remain Major Market Jurisdictions and whether additional countries should be designated
as Major Market Jurisdictions. If the Parties do not agree upon the designation of a country as a
Major Market Jurisdiction or whether a country should remain or cease to remain a Major Market
Jurisdiction, the Parties shall submit the matter to the JEC for resolution in accordance with
Section 2.1(d). Notwithstanding the foregoing provisions of this Section 4.3 relating to the
assessment, designation and review of Major Market Jurisdiction, the Jurisdictions listed on
Schedule 4.3 are hereby categorized as Major Market Jurisdictions and shall not be subject to
redesignation as non-Major Market Jurisdictions. Each Party shall bear its own Costs incurred in
assessing, designating and reviewing Major Market Jurisdictions in accordance with this Section
4.3(a).

          (b) In at least one Major Market Jurisdiction (“First Major Market Jurisdiction”),
Alpharma will either (i) initiate local Clinical Trials for a Product within [**] following U.S.
Regulatory Approval or (ii) if local Clinical Trials are not required for Regulatory Approval in
the First Major Market Jurisdiction, file an application for Regulatory Approval within [**]
following U.S. Regulatory Approval. In at least one additional Major Market Jurisdiction
(“Second Major Market Jurisdiction”), Alpharma will either (A) initiate local Clinical
Trials for a Product within [**] following U.S. Regulatory Approval or (B) if local Clinical
Trials are not required for Regulatory Approval in the Second Major Market Jurisdiction, file an
application for Regulatory Approval within [**] following U.S. Regulatory Approval. If
Subterritory C is not the First Major Market Jurisdiction or the Second Major Market Jurisdiction,
then in addition to the foregoing requirements regarding the First Major Market Jurisdiction and
the Second Major Market Jurisdiction, Alpharma will either (A) initiate local Clinical Trials for
a Product in Subterritory C within [**] following U.S. Regulatory Approval or (B) if local
Clinical Trials are not required for Regulatory Approval in Subterritory C, file an application
for Regulatory Approval within [**] following U.S. Regulatory Approval. In all other Major Market
Jurisdictions, Alpharma will use
Commercially Reasonable Efforts to either (I) initiate local Clinical Trials for a Product
within [**] following U.S. Regulatory Approval or (II) if local Clinical Trials are not required
for Regulatory Approval in any such other Major Market Jurisdiction, file an application for
Regulatory Approval within [**] following U.S. Regulatory Approval. For the avoidance of doubt,
the filing of a Regulatory Approval Application with EMEA shall constitute filing of a

CONFIDENTIAL

28

 

Regulatory
Approval Application in all Major Market Jurisdictions that are subject to EMEA’s regulatory
authority, and initiating Clinical Trials for the purpose of supporting the filing of a Regulatory
Approval Application with EMEA shall constitute initiating local Clinical Trials with respect to
all Major Market Jurisdictions that are subject to EMEA’s regulatory authority.

          (c) After satisfying the requirements of Section 4.3 with respect to a Major Market
Jurisdiction, Alpharma shall use Commercially Reasonable Efforts to obtain Regulatory Approval for
and to Commercialize the Product in such Major Market Jurisdiction. [**].

          (d) If Alpharma fails to satisfy its obligations under this Section 4.3 with respect to a
Major Market Jurisdiction, Durect shall thereafter have the right to terminate Alpharma’s rights
in such Major Market Jurisdiction if Alpharma has not cured such failure within the [**] period
following written notice of termination by Durect; provided, however, if the
failure is not reasonably capable of being cured within the [**] cure period by Alpharma and
Alpharma is making a good faith effort to cure such failure, Durect may not terminate Alpharma’s
rights in such Major Market Jurisdiction; provided further, however, that
Durect may terminate Alpharma’s rights in such Major Market Jurisdiction if such failure is not
cured within [**] of Durect’s original notice of termination. Notwithstanding the foregoing,
Alpharma shall be deemed to have satisfied its obligations under this Section 4.3 and shall retain
rights to all Jurisdictions in the EU provided that Alpharma has satisfied its development and
Commercialization obligations under this Section 4.3 in at least [**] of the Major Market
Jurisdictions which are part of the EU. The Major Market Jurisdictions with respect to which
Durect has terminated Alpharma’s rights hereunder will thereafter be deemed Terminated Countries
and no longer be included in the Territory, and Durect shall have the rights set forth in Section
13.7 in such Terminated Countries. The foregoing termination rights of Durect shall be Durect’s
sole and exclusive remedy and Alpharma’s sole and exclusive liability for any
failure by Alpharma to develop and Commercialize the Product in any Major Market
Jurisdiction.

          (e) Except as otherwise set forth in Section 4.3(a), if any dispute arises between the
Parties regarding the matters set forth in Section 4.3, then such matter shall be submitted for
resolution in accordance with Section 14.12.

CONFIDENTIAL

29

 

     4.4 Other Development Matters.

          (a) Prior to the first Regulatory Approval of the Product, Alpharma will provide to Durect
draft forms of protocols for all studies required for seeking a label indication in Subterritory A
and the Major Market Jurisdictions. Alpharma shall consider in good faith all comments provided
by Durect in writing within the [**] period following Durect’s receipt of such protocols; provided
that Alpharma shall have the sole discretion and authority to make all decisions with respect to
final protocols and all other matters relating to development of the Product. Alpharma shall
promptly provide Durect with a copy of all final reports and final protocols from Preclinical and
Non-Clinical trials and Clinical Trials in Subterritory A and the Major Market Jurisdictions.

          (b) Promptly following, and in any event not later than [**] following, the Effective Date,
Durect shall (i) transfer and assign to Alpharma ownership of all INDs held by Durect for the
Product in the Territory, if any, including copies of any Regulatory Documentation regarding the
Product in the Territory and (ii) transfer and assign to Alpharma, or to any Affiliate that
Alpharma may specify, ownership of the Orphan Drug Designation received by Durect with respect to
the Bupivacaine for PHN as described in Schedule 4.4 hereto and all other regulatory exclusivity
rights, if any, held by Durect and its Affiliates with respect to the Product. In addition,
promptly following the Effective Date, Durect shall transfer to Alpharma copies of all Development
Data in existence as of the Effective Date. After such transfers and assignments by Durect,
Alpharma shall be responsible for all Product-related reporting and other obligations to any
Regulatory Authorities.

          (c) During the period that the JDC remains in existence, all significant Product-related
regulatory decisions within the Subterritory A and the Major Market Jurisdictions shall be subject
to review of the JDC. Durect shall have the right to review and comment upon material portions of
regulatory filings and correspondence regarding major or material issues proposed to be made or
sent with respect to the Product in Subterritory A and the Major Market Jurisdictions prior to
their submission to Regulatory Authorities, provided that (i) such review
opportunity may be provided by electronic access to drafts of such documents, (ii) the Alliance
Managers will (with oversight from the JDC) coordinate the scope, timing and form of such document
access in a manner that seeks to minimize administrative burden and (iii) for

CONFIDENTIAL

30

 

any comments from Durect to be considered, the comments shall be provided promptly and
reasonably in advance of any deadlines or target dates for submission. Alpharma shall promptly
provide to Durect copies of or electronic access to material portions of all such filings and
correspondence from or to such Regulatory Authorities concerning the Product in Subterritory A and
the Major Market Jurisdictions, provided that the Alliance Managers will (with
oversight from the JDC) coordinate the scope, timing and form of all such document access in a
manner that seeks to minimize administrative burden. With regard to the NDA in Subterritory A,
Durect shall, at Alpharma’s request, assist Alpharma in creating and finalizing Modules 2 and 3.
In addition, Durect shall, at Alpharma’s request, provide input for the creation and review of the
Integrated Summary of Safety and the Integrated Summary of Efficacy. Upon request by Durect,
other NDA sections or Modules will be available for review. At the request of Alpharma, Durect
shall participate, at Alpharma’s Cost, in any conference or meeting with Regulatory Authorities
with respect to the Product in Subterritory A and the Major Market Jurisdictions. Alpharma shall
notify Durect in writing of its receipt of Regulatory Approval to market the Product in any
Jurisdiction within [**] after receipt of any such approval.

     4.5 Line Extensions. In the event that Alpharma desires to develop Line Extensions to
the Product which Alpharma deems beneficial to the Commercialization of the Product in the
Territory, Alpharma shall deliver to the JEC a written proposal summarizing the proposed Line
Extension together with a plan summarizing the activities necessary to develop the Line Extension
through Regulatory Approval in the Territory similar to the approach outlined in the Development
Plan. Upon receipt of such documentation, the JEC shall meet to discuss and consider such proposed
Line Extension and approve any plans and budgets for any Durect Development Responsibilities. The
Line Extension shall be encompassed in the definition of “Product” under the Agreement, and subject
to all the terms and conditions applicable thereto under this Agreement.

     4.6 Durect Development Responsibilities.

     (a) Notwithstanding anything herein to the contrary, the following activities with respect to
Product development are allocated to Durect (collectively “Durect Development
Responsibilities”): (i) unless otherwise agreed upon by the Parties, all

 CONFIDENTIAL

31

 

development activities through completion of Phase 2 [**]; (ii) Dosage Form Development;
(iii) manufacturing and analytical method development, validation, stability and other CMC-related
activities; (iv) management of any and all technology transfer, scale-up to commercial batch size
and validation activities that may be required to enable any Person chosen by Alpharma to
manufacture commercial supplies of the Product; (v) generation of necessary documents related to
the Durect Development Responsibilities in order for Alpharma to perform Clinical Trials and file
for Regulatory Approval in the Territory; and (vi) any other development activity allocated to
Durect by Alpharma and agreed to by Durect. Durect shall use Commercially Reasonable Efforts to
perform the Durect Development Responsibilities in accordance with the Development Plan (including
Development Plan Budget and timeline set forth therein) for such Durect Development
Responsibilities.

          (b) Subject to Section 7.5, Alpharma shall pay to Durect its Durect Development Costs
incurred with the performance of the Durect Development Responsibilities on a monthly basis, net
[**] from the receipt of an invoice therefor from Durect; provided that Alpharma shall have no
obligation to reimburse Durect’s Development Costs in excess of the then-current Development Plan
Budget, and Durect shall have no obligation to perform activities which would result in Durect
incurring costs in excess of the then-current Development Plan Budget, in each case, until the JEC
has approved any increase the Development Plan Budget.

          (c) Durect may, with the prior written consent of Alpharma (not to be unreasonably withheld,
delayed or conditioned), retain Third Party contractors to perform some or all of the Durect
Development Responsibilities so long as the Third Party is subject to the applicable terms of this
Agreement, including confidentiality obligations to Durect that are no less stringent than the
confidentiality obligations set forth in Section 10, and agrees to assign ownership of all work
product and intellectual property rights relating to the Product resulting from such work to
Durect. Durect’s selection of such Third Parties are subject to the prior written approval of
Alpharma, such approval not to be unreasonably withheld, and all Durect Development Costs
resulting from such Third Parties’ work shall be subject to audit by Alpharma. Durect will remain
responsible to Alpharma for all Durect Development Responsibilities carried out by such Third
Party contractors.

 CONFIDENTIAL

32

 

     (d) In the event that Durect [**] included in the Durect Development Responsibilities, and
provided that such [**] (i) [**] or (ii) [**] such Durect Development Responsibilities, then [**]
such task included in the Durect Development Responsibilities [**].

     4.7 Development Data. Alpharma will exclusively own all Development Data which comes
into existence after the Effective Date, and Durect hereby assigns to Alpharma all rights, title
and interests therein Controlled by Durect or any of its Affiliates.

     4.8 Reporting Adverse Events. Commencing on the Effective Date, as between the
Parties, Alpharma shall be responsible for collection, investigation, reporting of information
concerning adverse events with respect to the Product (as defined in the then current edition of
ICH Guidelines and any other relevant regulations or regulatory guidelines) or any other safety
problem of significance (each such adverse event or problem, an “Adverse Event”) to the
appropriate Regulatory Authorities in the Territory in accordance with Applicable Laws. Alpharma
will require that its Affiliates and Sublicensees comply with all Adverse Event reporting
obligations. In any event, Alpharma shall inform Durect of any Serious Adverse Drug Experience
relating to the Product or Bupivacaine of which it becomes aware in a timely manner commensurate
with the seriousness of the Adverse Event.

     4.9 Permitted Development Personnel. During the Term of the Agreement, each Party
will not engage, retain or employ any employees, subcontractors or consultants to perform any part
of the Development Program that (A ) have been debarred or convicted of a crime for which an entity
or person could be debarred under 21 U.S.C. Section 335a (or equivalent law in any applicable
Jurisdiction), or (B) is under indictment for a crime for which a person or an entity could be
debarred under 21 U.S.C. Section 335a (or equivalent law in any applicable Jurisdiction).

5. DISTRIBUTION AND PROMOTION.

     5.1 Generally. As between the Parties, Alpharma will be exclusively responsible for
Commercializing the Product in the Territory and all Costs associated therewith.

     5.2 Post-Registration Studies. Alpharma shall prolong the life cycle of the Product
in Subterritory A and the Major Market Jurisdictions to the extent Alpharma determines it is
Commercially Reasonable to do so. If Alpharma performs any Phase 4 Clinical Trial or other

 CONFIDENTIAL

33

 

Clinical Trial of the Product in Subterritory A and the Major Market Jurisdictions following
receipt of Regulatory Approval for the Product (each, a “Alpharma Post-Registration
Study”), Alpharma shall provide Durect with draft forms of summary protocols for major studies
before commencement of any such study. Alpharma shall consider in good faith all comments provided
by Durect in writing within the [**] period following Durect’s receipt of such protocols; provided,
that Alpharma shall have the sole discretion and authority to make all decisions with respect to
the final protocols and all other matters relating to Alpharma Post-Registration Studies. Alpharma
shall also promptly provide to Durect a copy of final protocols and reports from such Alpharma
Post-Registration Studies. Alpharma shall bear the Costs of all Alpharma Post-Registration
Studies. For the avoidance of doubt, Alpharma Post-Registration Studies shall include any Clinical
Trials required as a condition to, or for the maintenance of, Regulatory Approval of the Product in
Subterritory A and the Major Market Jurisdictions.

     5.3 Alpharma Responsibilities; Rights. In connection with its responsibilities for
distribution, marketing and sales of the Product in the Territory, Alpharma shall, at its Cost,
provide for all sales force personnel (including sales administration and training), order entry,
customer service, reimbursement management, medical affairs, medical information, marketing
(including all advertising and promotional expenditures), warehousing, physical distribution,
invoicing, credit and collections, forecasting and other related facilities and services necessary
for such Commercialization.

     5.4 Annual Commercialization Reports. Following the end of each fiscal year after
the First Commercial Sale of the Product in Subterritory A or any Major Market Jurisdiction,
Alpharma shall provide Durect with an annual summary of Alpharma’s efforts and plans for the
Commercialization of the Product in Subterritory A and the Major Market Jurisdictions as
applicable. In addition, the Alpharma Alliance Manager shall provide reasonable summary
information concerning Commercialization matters to the Durect Alliance Manager from time to time,
as reasonably requested by Durect. To the extent commercially feasible and permitted by Applicable
Laws, all promotional materials shall include an acknowledgment of Durect as the developer and
licensor of the Product.

     5.5 Sales Forces. Alpharma shall employ or contract appropriately experienced sales
forces to detail the Product in Subterritory A and the Major Market Jurisdictions in which

 CONFIDENTIAL

34

 

Regulatory Approvals for the Product are obtained, and [**]. In addition, Alpharma agrees
that for the [**] after First Commercial Sale of the Product in Subterritory A and the Major Market
Jurisdictions in which Regulatory Approvals for the Product are obtained, the sales force will
promote the Product [**].

6. PAYMENTS.

     6.1 One-time Payments to Durect. Alpharma shall, against invoice, pay to Durect the
following one-time, non-refundable and non-creditable payments (each a “One-Time Payment”)
within [**] after the occurrence of the specific event (in the case of the One-Time Payment payable
upon the occurrence of Milestone No. 1 set forth in the table below), within [**] after the
occurrence of the specific event (in the case of each of the One-Time Payments payable upon the
occurrence of Milestone Nos. 2 — 12 set forth in the table below) and concurrently with the payment
of Royalties based on the applicable quarterly report (in the case of each of the One-Time Payments
payable upon the occurrence of Milestone Nos. 13 — 15 set forth in the table below). The One-Time
Payments will be part of the consideration for the license granted in Section 3.1.

	 	 	 	 	 
	Milestone	 	 	 	One-Time Payments to
	No.	 	Timing	 	Durect (U.S. Dollars)
	1

	 	The Effective Date of this Agreement
	 	Twenty Million Dollars

($20,000,000)

[**]

Each Party shall promptly notify the other Party when any event triggering a One-Time Payment
listed above has occurred, with payments [**] based on the latest quarterly report due [**] after
the end of the applicable quarter.

     6.2 Royalties. Subject to the other provisions of this Section 6, Alpharma shall pay
Royalties to Durect in respect of the license granted to Alpharma by Durect hereunder on a
Jurisdiction-by-Jurisdiction basis for the applicable Royalty Term. In a Jurisdiction where the
Patent Royalty Term is in effect, Alpharma shall owe Durect Patent Royalties with respect to
calendar year Net Sales of Product in such Jurisdiction. In a Jurisdiction where the Know-How
Royalty Term is in effect, Alpharma shall owe Durect Know-How Royalties with respect to calendar
year Net Sales of Product in such Jurisdiction. The aggregate of all Patent Royalties

 CONFIDENTIAL

35

 

and Know-How Royalties that are due to Durect in any Annual Net Sales Period (as defined
below) shall be referred to herein as “Royalties.”

          (a) Patent Royalties. Patent Royalties shall begin to accrue in accordance with the charts set
forth below, on a Jurisdiction-by-Jurisdiction basis, on Net Sales within the Territory during the
period commencing on the date of the First Commercial Sale of the Product in such Jurisdiction and
shall be payable until, the later of the expiration of (i) all Patents containing one or more Valid
Claims that would be infringed by the development, manufacture, sale, offer for sale, use,
importation or exportation of the Product, or (ii) Marketing Exclusivity Rights in such
Jurisdiction (such period the “Patent Royalty Term”). Notwithstanding the foregoing
however, if, during a given calendar quarter during the Patent Royalty Term, there is a Generic
Product commercially sold by a Third Party in a Jurisdiction, then so long as such Generic Product
is being sold by such Third Party, the Royalties due with respect to Net Sales in such Jurisdiction
for such quarter during the Patent Royalty Term shall be reduced by [**] percent ([**]%) of the
rates set forth in the charts below in this Section 6.2(a).

For Sales in Subterritory A

	 	 	 
	Aggregate Annual Net Sales in	 	 
	Subterritory A	 	Royalty to Durect (percent of Net Sales)
	Up to $[**] annual sales:

	 	[**] %
	>$[**] annual sales:

	 	[**] %
	>$[**] annual sales:

	 	[**] %
	>$[**] annual sales:

	 	[**] %
	>$[**] annual sales:

	 	[**] %

For Sales in Subterritory B, Subterritory C and Subterritory D in the aggregate

	 	 	 
	Aggregate Annual Net Sales in	 	 
	Subterritory B, Subterritory C and	 	 
	Subterritory D	 	Royalty to Durect (percent of Net Sales)
	Up to $[**] annual sales:

	 	[**] %
	>$[**] annual sales:

	 	[**] %
	>$[**] annual sales:

	 	[**] %
	>$[**] annual sales:

	 	[**] %

 CONFIDENTIAL

36

 

The Royalty rates set forth above shall apply only to that portion of Net Sales within the
applicable tier of Net Sales.

The periods by which annual Net Sales are measured for purposes of this Section 6.2 shall be a
calendar year (each, an “Annual Net Sales Period”) except that the first Annual Net Sales
Period shall begin on the first day of the calendar quarter preceding the First Commercial Sale and
continue to the end of the calendar quarter ending on December 31st of that calendar
year. For purposes of illustration, see Example 1 in Schedule 6.2.

     (b) Know-How Royalties. Know-How Royalties shall accrue, on a
Jurisdiction-by-Jurisdiction basis, on Net Sales in the Jurisdiction during any portion of the
applicable Royalty Term that remains after the expiration of the applicable Patent Royalty Term
(the “Know-How Royalty Term”). Subject to the other provisions of this Section 6, if the
Know-How Royalty Term is in effect in a Jurisdiction, Alpharma shall pay Durect Know-How Royalties
with respect to the aggregate annual Net Sales in such Jurisdiction at a rate of [**]% of the
rates set forth in the tables set forth in Section 6.2(a). The first Annual Net Sales Period in
which Know-How Royalties are payable shall begin on the first day of the Know-How Royalty Term and
continue to the end of the calendar quarter ending on December 31st of that calendar
year. For purposes of illustration, see Example 2 in Schedule 6.2.

     6.3 Sublicense Income. In addition to the Royalties payable to Durect under Section
6.2 and the One-Time Payments payable to Durect under Section 6.1, if Alpharma grants a Sublicense
under Section 3.2 with respect to a Jurisdiction, Alpharma shall thereafter pay Durect, within [**]
after the receipt thereof by Alpharma, [**] percent ([**]%) of the portion of any Sublicense Fees
received by Alpharma that exceeds the aggregate of all One-Time Payments payable by Alpharma to
Durect with respect to such Jurisdiction.

     6.4 Existing Third Party Royalties. Durect shall be solely responsible for payment of
[**] percent ([**]%) of all financial obligations to [**] under the [**] Agreement.

7. PAYMENTS AND REPORTS.

     7.1 Payments of Royalties. Beginning [**] after the end of the calendar quarter in
which the First Commercial Sale is made and for each calendar quarter thereafter (no later than
[**] after the end of such calendar quarter), Alpharma shall submit a statement to Durect, which
shall

 CONFIDENTIAL

37

 

set forth the amount of Net Sales in the Territory by Jurisdiction, during such quarter, and
the calculation of Royalties due on such Net Sales in each Jurisdiction and in the aggregate for
the Territory for such quarter. Each such statement shall be accompanied by the payment, if any,
due to Durect.

     7.2 Mode of Payment for One-Time Payments and Royalties. Alpharma shall make all
payments required under this Agreement by wire transfer to any account specified by Durect or as
otherwise directed by Durect from time to time in Dollars.

     7.3 Currency Conversion. Royalties with respect to any Net Sales in Jurisdictions
where the Dollar is not used as currency shall be calculated by converting the amount of Net Sales
into the corresponding amount in Dollars and applying the applicable Royalties percentage under
Section 6 to such amount. The currency conversion shall be made using the average of the rates of
exchange for the conversion of the currency in which sales were made to Dollars over the calendar
quarter during which such sales were made, as such rates are published by the Wall Street
Journal, Western Edition.

     7.4 Records Retention. Alpharma, its Sublicensees, Durect and each such Party’s
respective Affiliates shall keep complete and accurate records pertaining to Durect Development
Costs and the sale of Product and the calculation of Net Sales in the Territory, as applicable, to
permit the determination of Durect Development Costs and Royalties for a minimum period of [**]
after the calendar year in which such sales or costs were occurred, and in sufficient detail to
permit the Parties to confirm the accuracy of each of the foregoing.

     7.5 Audit Request. During the Term of this Agreement and for a period of [**]
thereafter, at the request and Cost of a Party (the “Auditing Party”), Durect and its
Affiliates (in the case of a request by Alpharma) or Alpharma and its Affiliates and Sublicensees
(in the case of a request by Durect) (the “Audited Party”) shall permit an independent,
certified public accountant appointed by the Auditing Party and reasonably acceptable to the
Audited Party, at reasonable times and upon reasonable advance notice of not less than [**], but
not more often than [**] in each calendar year, to examine such records during the [**] prior to
the notice as may be necessary to determine the correctness of any report or payment made under
this Agreement or obtain information as to the determination of the Durect Development Costs, Net
Sales and Royalties payable for any calendar quarter in such audited period. Results of any such

 CONFIDENTIAL

38

 

examination shall be made available to all Parties except that said independent, certified
public accountant shall verify to the Auditing Party such amounts and shall disclose no other
information revealed in such audit. The examination shall also include disclosure of the
methodology and calculations used to determine the results. The said independent, certified public
accountant shall execute a written confidentiality agreement with the Audited Party.

     7.6 Cost of Audit. The Auditing Party shall bear the full Cost of the performance of
any audit requested by the Auditing Party except as hereinafter set forth. If, as a result of any
inspection of the books and records of the Audited Party, it is shown that payments made by one
Party to the other under this Agreement were less than the amount which should have been paid (in
the case of Royalties) or the amount of costs charged by one Party to the other Party were more
than the amount that should have been charged (in the case of Durect Development Costs), then the
under-paying or over-charging Party, as applicable, shall make all payments required to be made to
eliminate any discrepancy revealed by said inspection within [**], including in each case interest
at the rate of [**] percent ([**]%) per month (or the maximum interest allowable by Applicable Law,
whichever is less) for the amount of the discrepancy. Furthermore, if the payments made were less
than [**] percent ([**]%) of the amount that should have been paid during any calendar year, or if
there was an overcharge of more than [**] percent ([**]%) of the amount of that was owed, in either
case due to the error of the Audited Party, the Audited Party shall also reimburse the Auditing
Party for reasonable Costs incurred by the Auditing Party in respect of such audit.

     7.7 No Non-Monetary Consideration for Sale. Alpharma and its Sublicensees and
Affiliates shall not accept or solicit any non-monetary consideration for the sale of the Product
without the prior written consent of Durect, provided, however, the use by Alpharma and its
Affiliates of a customary and reasonable amount of the Product for promotional sampling,
compassionate use or donations shall not violate this Section 7.7.

8. COMMERCIAL SUPPLY OF PRODUCT

     8.1 Responsibility. Alpharma shall use Commercially Reasonable Efforts, at its sole
Cost, to manufacture the Product for Clinical use and Commercialization in the Territory in
compliance with the terms and conditions of this Agreement. At Alpharma’s election, Durect shall
assign the [**] Agreement to Alpharma within [**] of the Effective Date.

 CONFIDENTIAL

39

 

     8.2 Technology Transfer. In the event that Alpharma elects to have Product
manufactured by itself or a CMO other than [**], Durect shall use Commercially Reasonable Efforts
to provide in a timely manner such of Manufacturing Technology Controlled by Durect in order for
Alpharma or the CMO selected by Alpharma to manufacture the Product, and shall use Commercially
Reasonable Efforts to provide technical assistance to enable the use of such Manufacturing
Technology to manufacture the Product, such assistance to be detailed in a technology transfer plan
to be agreed upon by the Parties (the “Technology Transfer Plan”). Alpharma shall
reimburse Durect its Durect Development Costs incurred in providing the Manufacturing Technology
and technical assistance in accordance with a budget therefor to be agreed by the Parties in
advance. Durect shall be reimbursed by Alpharma on a monthly basis, within [**] of receipt of an
invoice setting forth such Durect Development Costs.

     8.3 Commercial Supply in Territory. Alpharma shall have sole responsibility (including
complete decision making authority and discretion) to manufacture or have manufactured Product for
the Commercialization of the Product in the Territory, and shall use Commercially Reasonable
Efforts to maintain or arrange for sufficient manufacturing capacity to meet the reasonably
anticipated market demand for the Product in the Territory.

9. INTELLECTUAL PROPERTY.

     9.1 Ownership of Collaboration Inventions. Subject to the terms hereof, including the
licenses and other rights granted hereunder, all Collaboration Inventions shall be owned as
follows:

     (a) [**] Collaboration Inventions (including all Patents and other Intellectual Property
Rights relating thereto) that relate to the Product (including, inter alia, components thereof,
its composition or formulation, methods of manufacture, processing, finishing, packaging and
methods of use), without regard to inventorship (each such Collaboration Invention a “Product
Collaboration Invention”).

     (b) With respect to Collaboration Inventions that do not constitute Product Collaboration
Inventions, [**] such Collaboration Inventions (including all Patents and other Intellectual
Property Rights relating thereto) [**] its employees and/or Third Parties acting on behalf of
Durect in the performance of the Development Plan and other activities undertaken by it under this
Agreement (each such Collaboration Invention a [**].

 CONFIDENTIAL

40

 

          (c) With respect to Collaboration Inventions that do not constitute Product Collaboration
Inventions, [**] such Collaboration Inventions (including all Patents and other Intellectual
Property Rights relating thereto) [**] its employees and/or Third Parties acting on behalf of
Alpharma in the performance of the Development Plan and other activities undertaken by it under
this Agreement (each such Collaboration Invention, an [**].

          (d) With respect to Collaboration Inventions that do not constitute Product Collaboration
Inventions, the Parties shall jointly own all Joint Inventions (as defined below) and, subject to
the rights granted each Party under this Agreement and except as otherwise specifically provided
under this Agreement, each Party may make, use, sell, keep, license or assign its interest in
Joint Inventions and otherwise undertake all activities a sole owner might undertake with respect
to such Joint Inventions, without the consent of and without accounting to the other Party.
“Joint Invention” means a Collaboration Invention which is not a Product Collaboration
Invention for which: (i) one or more employees, consultants or agents of Durect or any other
persons obligated to assign such Collaboration Invention to Durect; and (ii) one or more
employees, consultants or agents of Alpharma or any other persons obligated to assign such
Collaboration Invention to Alpharma, are joint inventors of such Collaboration Invention. The
term “joint inventors,” as it applies generally to Collaboration Inventions, shall be construed in
accordance with how that term is used pursuant to United States patent law.

          (e) Subject to appropriate confidentiality undertakings, each Party shall notify the other
Party promptly after the completion of invention disclosure statements (or similar type of
internal process employed by such Party for recording or recognizing inventions) for each
Collaboration Invention (or, if any provisional or other patent application is filed claiming such
invention, promptly upon such filing), and shall provide a copy of written documentation of the
Collaboration Invention suitable to describe the invention and identify any inventors
participating in the invention (or, if any patent application is filed, a full and complete copy
of the documents submitted to the relevant patent office) to the other Party.

          (f) Each Party may use and practice its own Collaboration Inventions in any manner not
inconsistent with the terms of this Agreement without the consent of the other Party and without
an obligation to notify the other Party of such intended use or to pay royalties or other
compensation to the other by reason of such use. For the avoidance of doubt,

 CONFIDENTIAL

41

 

neither Party is granted any license rights to any Intellectual Property Rights of the other
Party which may be required for such Party to use a Collaboration Invention, unless otherwise
expressly granted herein or as may be necessary to fulfill the intent of this Agreement.

          (g) Each Party shall, at the request of the other Party, execute all assignment documents
necessary to perfect the ownership interests in Collaboration Inventions as determined pursuant to
this Section 9.1. Each Party hereby agrees that Development Data owned by such Party may be
included in patent and patent applications covering Collaboration Inventions owned by the other
Party as reasonably useful to the filing and prosecution of such patent applications and patents,
and the Party owning such Development Data shall reasonably cooperate with the other Party to
allow for such inclusion.

          (h) Each Party has and will continue to have written contracts with all Third Parties
(including employees and subcontractors) performing services on its behalf under this Agreement
and, where such services may give rise to the creation of inventions that may be Collaboration
Inventions, such Party shall ensure that such contracts provide for the assignment to such Party
all Collaboration Inventions and rights therein; provided, however,
notwithstanding the foregoing, Alpharma may enter into Third Party contract manufacturing
agreements for the sole purpose of having the Product manufactured for Alpharma that do not
require such Third Party manufacturers to assign any Collaboration Inventions that are
manufacturing process inventions to Alpharma if such Third Party manufacturers do not agree to the
assignment of such manufacturing process Collaboration Inventions.

     9.2 Prosecution of Patents.

          (a) Durect Controlled Patents.

          (i) As between Durect and Alpharma, Durect shall prepare, prosecute and maintain the
[**], Product Patent Rights and [**] (including their issuance, reissuance, reexamination
and the defense of any interference, revocation or opposition proceedings) at Durect’s sole
Cost and discretion subject to the provisions of this Section 9.2(a).

          (ii) With respect to Product Patent Rights, Durect shall furnish Alpharma with copies
of all substantive prosecution correspondence to and from patent

 CONFIDENTIAL

42

 

offices in the Territory and provide Alpharma a reasonable time to offer its comments
thereon before Durect makes a submission to the relevant patent office, provided that in the
event that delay would jeopardize any potential Product Patent Right, Durect shall have the
right to proceed without awaiting Alpharma’s comments on any patent application or
correspondence relating thereto. Alpharma shall offer its comments promptly, and Durect
shall consider in good faith such comments of Alpharma and shall incorporate such comments
if reasonable. Durect shall not abandon any patent application or patent in the Product
Patent Rights without the prior written consent of Alpharma, such consent not to be
unreasonably withheld or delayed. If, subject to Alpharma’s foregoing consent right,
Durect determines to abandon, or not to file, prosecute, defend or maintain, any Product
Patent Right (including not to defend any interference, revocation or opposition
proceedings) in any Jurisdiction, then Durect shall provide Alpharma with [**] prior written
notice (or such shorter time period that would permit Alpharma a reasonable opportunity to
respond without any loss of rights) of such determination, and Alpharma shall have the right
and opportunity to file, prosecute, defend and/or maintain such Product Patent Right in
Durect’s name and at Alpharma’s sole Cost and expense, provided, however, that the payment
of Costs therefor by Alpharma shall not affect Durect’s ownership in such Patent.

          (b) Joint Patents. With respect to the decision to initiate the drafting and filing
of a new patent application claiming a Joint Invention, the Parties shall first exchange
sufficient information identifying such Joint Invention and discuss in good faith the relative
merits of seeking patent rights thereto and, upon the prior mutual agreement of the Parties to
proceed, not unreasonably withheld, Alpharma shall take such actions as are necessary or
appropriate to procure, prosecute and maintain patents and/or patent applications to such Joint
Inventions (“Joint Patent Rights”) (including any issuance, reissuance or reexamination
thereof and the defense of any interference, revocation or opposition proceedings related thereto)
at Alpharma’s sole Cost and discretion, subject to the provisions of this Section 9.2(b);
provided, that all such Joint Patents shall be owned jointly. Alpharma shall furnish Durect with
copies of drafts of such Joint Patents and any substantive prosecution correspondence relating to
such Joint Inventions to and from patent offices throughout the Territory and permit Durect to
offer its comments thereon before Alpharma makes any submission or response to a patent office.

 CONFIDENTIAL

43

 

Alpharma will inform Durect of the countries in which it intends to file Joint Patents.
Durect shall offer its comments promptly, including any request that the Joint Patents be filed in
additional countries; provided, that Alpharma shall determine the appropriate action after
considering in good faith any comments or requests from Durect, and further provided that in the
event that delay would jeopardize any potential patent right, Alpharma shall have the right to
proceed without awaiting Durect’s comments. If Alpharma determines in its sole discretion not to
file, prosecute, defend or maintain any Joint Patent Rights (including failing to defend any
interference, revocation or opposition proceedings) in any country, then Alpharma shall provide
Durect with [**] prior written notice (or such shorter time period that would permit Durect a
reasonable opportunity to respond in a timely manner) of such determination, and Durect shall have
the right and opportunity to file, prosecute, defend and/or maintain such Joint Patent Rights on
behalf of the Parties at Durect’s sole Cost.

          (c) Alpharma Patents. As between Durect and Alpharma, Alpharma may prepare, prosecute
and maintain all Patents claiming an Alpharma Collaboration Invention (including their issuance,
reissuance, reexamination and the defense of any interference, revocation or opposition
proceedings) at Alpharma’s sole Cost and discretion.

          (d) Each Party shall, at the reasonable request of the other Party, execute all lawful
papers, all divisional, continuing, reissue and foreign applications, make all rightful oaths and
take such other actions as may be reasonably requested by the other Party in conjunction with
submission, filing, prosecution and defense of Patents and to aid in obtaining the proper
protection of inventions pursuant to this Section 9.2.

     9.3 Patent Certifications.

          (a) To the extent required or permitted by Applicable Laws, [**] shall use its Commercially
Reasonable Efforts to maintain with the applicable Regulatory Authorities in the Territory during
the Term of this Agreement correct and complete listings of applicable Patents covering the
Product, including in the U.S., all so called “Orange Book” listings required under the
Hatch-Waxman Act. In the event either Party receives notice that a Third Party has filed a patent
certification under the Hatch-Waxman Act or any successor statute (e.g., a Paragraph IV
Certification under 21 C.F.R. §314.50(i) or 314.94(a)(12)) referencing a Patent licensed under
Section 3.1, then such Party shall immediately notify the other Party in writing of such notice.

 CONFIDENTIAL

44

 

          (b) Alpharma shall have the first right, but not the duty, upon written notice to Durect to
institute an action against such Third Party alleging infringement of any Product Patent Rights,
and to the extent necessary, Durect shall assign to Alpharma its cause of action for infringement
of any Product Patent Rights against such Third Party. Alpharma shall consider in good faith all
comments provided by Durect within the [**] period following Durect’s receipt of such notice from
Alpharma regarding Alpharma’s intention to initiate an action against such Third Party alleging
infringement of any Product Patent Rights; provided that, subject to terms of Section
9.3(d), Alpharma shall have the sole discretion and authority to exercise its first right to
institute such a patent infringement action. If Alpharma determines not to institute an action
against such Third Party alleging infringement of any Product Patent Rights, Alpharma shall so
notify Durect at least [**] before the expiration of the period within which a patent holder may
bring an action for infringement against such Third Party. Durect shall then have the right, but
not the duty, to institute such an action against such Third Party alleging infringement of any
Product Patent Rights.

          (c) As between Durect and Alpharma, Durect shall have the first right, but not the duty, upon
written notice to Alpharma to institute an action against a Third Party for infringement of the
[**] in response to such Third Party’s filing of a Paragraph IV certification referencing such
Patent rights. Durect shall consider in good faith all comments provided by Alpharma within the
[**] period following Alpharma’s receipt of such notice from Durect regarding Durect’s intention
to initiate an action against such Third Party alleging infringement of the [**]; provided
that, subject to terms of Section 9.3(d), Durect shall have the sole discretion and authority
to exercise its first right to institute such a patent infringement action. If Durect determines
not to institute an action against such Third Party alleging infringement of the [**], Durect
shall so notify Alpharma at least [**] before the expiration of the period within which a patent
holder may bring an action for infringement against such Third Party. Alpharma shall then have
the right, but not the duty, to institute such an action against such Third Party alleging
infringement of the [**]; provided, however, that Alpharma’s right to undertake any such action
alleging infringement of the [**] shall be subject to the prior written consent of Durect, not to
be unreasonably withheld, and also the applicable terms of any agreements relating to the [**]
entered into by Durect prior to the Effective Date, and with

 CONFIDENTIAL

45

 

respect any actions alleging infringement of the [**], subject to the applicable terms of the
[**] Agreement.

          (d) The Costs of any such action under this Section 9.3 (including fees of attorneys and
other professionals) shall be borne by the Party instituting the action, or, if the Parties elect
to cooperate in instituting and maintaining such action, such Costs shall be borne by the Parties
in such proportions as they may agree in writing. For any such action to terminate any such
infringement, in the event that either Party is unable to initiate or prosecute such action solely
in its own name or it is otherwise advisable to obtain an effective remedy, the other Party will
join such action voluntarily and will execute and cause its Affiliates to execute all documents
necessary for the enforcing Party to initiate and maintain such action. Each Party shall at its
own expense promptly give to the Party bringing such infringement proceedings such reasonable
assistance as the Party bringing the action may reasonably request. The Party instituting any
such action may not enter into any settlement, consent judgment or other voluntary final
disposition of such action that admits the invalidity or unenforceability of any Patent licensed
hereunder, subjects the other Party to an injunction or requires the other Party to make any
monetary payment without the prior written consent of the other Party, not to be unreasonably
withheld by the other Party. The Party undertaking any proceedings shall keep the other
reasonably informed of the progress of the action and shall consider the comments and observations
of the other in prosecuting the proceedings. Any award paid by a Third Party as a result of such
an infringement action (whether by way of settlement or otherwise) shall be allocated in the same
manner as provided in Section 9.4.

     9.4 Enforcement of Patent Rights.

          (a) In the event that either Alpharma or Durect becomes aware of any Competitive Product that
is or is intended to be made, used, or sold in the Territory by a Third Party that it believes to
infringe Product Patent Rights, [**], such Party will promptly notify the other Party of all the
relevant facts and circumstances known by it in connection with the infringement. Alpharma and
Durect shall thereafter consult and cooperate fully to determine a course of action, including the
commencement of legal action as provided in this Section 9.4 by either or both Parties, to
terminate any such infringement.

 CONFIDENTIAL

46

 

          (b) As between Durect and Alpharma, Alpharma shall have the first right, but not the duty,
upon written notice to Durect to initiate, prosecute and control the enforcement of any of the
Product Patent Rights against infringement by a Third Party in the Territory through the marketing
or sale of a Competitive Product. If Alpharma does not institute a proceeding against such Third
Party alleging infringement of a Product Patent Right within [**] of a Party’s first notice to the
other Party of such Third Party infringement, then Durect shall have the right, but not the duty,
to institute such an action against such Third Party for infringement of such Product Patent
Right.

          (c) As between Durect and Alpharma, Durect shall have the first right, but not the duty, upon
written notice to Alpharma to initiate, prosecute and control the enforcement of any of the [**]
against infringement by a Third Party in the Territory through the marketing or sale of a
Competitive Product. If Durect does not institute a proceeding against such Third Party alleging
infringement of the [**] within [**] of a Party’s first notice to the other Party of such Third
Party infringement, then Alpharma shall have the right, but not the duty, to institute such an
action against such Third Party for infringement of any of the [**]; provided, however, that
Alpharma’s right to undertake any such action alleging infringement of the [**] shall be subject
to the prior written consent of Durect, not to be unreasonably withheld and also the applicable
terms of any agreements relating to the [**] entered into by Durect prior to the Effective Date,
and with respect any actions alleging infringement of the [**], subject to the applicable terms of
the [**] Agreement.

          (d) The Costs of any such action under this Section 9.4 (including fees of attorneys and
other professionals) shall be borne by the Party instituting the action, or, if the Parties elect
to cooperate in instituting and maintaining such action, such Costs shall be borne by the Parties
in such proportions as they may agree in writing. For any such action to terminate any such
infringement, in the event that either Party is unable to initiate or prosecute such action solely
in its own name or it is otherwise advisable to obtain an effective remedy, the other Party will
join such action voluntarily and will execute and cause its Affiliates to execute all documents
necessary for the enforcing Party to initiate and maintain such action. Each Party shall at its
own expense promptly give to the Party bringing such infringement proceedings such reasonable
assistance as the Party bringing the action may reasonably request. The Party instituting any
such action may not enter into any settlement, consent

 CONFIDENTIAL

47

 

judgment or other voluntary final disposition of such action that admits the invalidity or
unenforceability of any Patent licensed hereunder, subjects the other Party to an injunction or
requires the other Party to make any monetary payment without the prior written consent of the
other Party, not to be unreasonably withheld by the other Party. The Party undertaking any
proceedings shall keep the other reasonably informed of the progress of the action and shall
consider the comments and observations of the other in prosecuting the proceedings.

          (e) Any recovery obtained as a result of an infringement action brought under this Section
9.4, whether by judgment, award, decree or settlement, will first be applied to reimbursement of
each Party’s Costs in bringing such suit or proceeding, and any remaining balance will be
distributed as follows:

          (i) if Alpharma has instituted and maintained such action alone, Alpharma shall be
entitled to retain [**] less [**], which [**] shall be paid to Durect. The [**] shall mean
[**] in the Annual Net Sales Period in which such remaining funds are received on such
remaining funds [**];

          (ii) if Durect has instituted and maintained such action alone, Durect shall be
entitled to retain [**] less the [**], which [**] shall be paid to Alpharma; or

          (iii) if the Parties have cooperated in instituting and maintaining such action, the
Parties shall allocate such remaining funds among themselves in the same proportion as they
have agreed to bear the Costs of instituting and maintaining such action.

     9.5 Defense of Patents.

          (a) In the event that either Alpharma or Durect becomes aware of any action initiated by a
Third Party (or any counterclaim or defense asserted in any other action) in the Territory
alleging invalidity or unenforceability of any Product Patent Rights, [**], such Party will
promptly notify the other Party of all the relevant facts and circumstances known by it in
connection with such action. Alpharma and Durect shall thereafter consult and cooperate fully to
determine a course of action.

          (b) Alpharma shall have the first right but not the duty to defend and control any action
initiated by a Third Party (or any counterclaim or defense asserted in any other

 CONFIDENTIAL

48

 

action) in the Territory alleging invalidity or unenforceability of any Product Patent
Rights. If Alpharma fails to defend any such action initiated by a Third Party (or any
counterclaim or defense asserted in any other action) within [**] of notice from such Third Party
(or such shorter time period that would permit Durect a reasonable opportunity to respond in a
timely manner), Durect shall thereafter have the right to defend and control any such invalidity
action, counterclaim or defense in the Territory.

          (c) Durect shall have the first right but not the duty to defend and control any action
initiated by a Third Party (or any counterclaim or defense asserted in any other action) in the
Territory alleging invalidity or unenforceability of the [**]. If Durect fails to defend any such
action initiated by a Third Party (or any counterclaim or defense asserted in any other action)
within [**] of notice from such Third Party (or such shorter time period that would permit
Alpharma a reasonable opportunity to respond in a timely manner), then Alpharma shall have the
right, but not the duty, to defend and control any such invalidity action, counterclaim or defense
in the Territory; provided, however, that Alpharma’s right to undertake any the defense of such
action relating to the [**] shall be subject to the prior written consent of Durect, not to be
unreasonably withheld and also the applicable terms of any agreements relating to the [**] entered
into by Durect prior to the Effective Date, and with respect any actions defending the [**],
subject to the applicable terms of the [**] Agreement.

          (d) The Costs of any such action under this Section 9.5 (including fees of attorneys and
other professionals) shall be borne by the Party defending the action, or, if the Parties elect to
cooperate in instituting and maintaining such action, such Costs shall be borne by the Parties in
such proportions as they may agree in writing. For any such action, in the event that either
Party is unable to defend such action solely in its own name or it is otherwise advisable to
obtain an effective remedy, the other Party will join such action voluntarily and will execute and
cause its Affiliates to execute all documents necessary for the defending Party to defend such
action. Each Party shall at its own expense promptly give to the defending Party such reasonable
assistance as the Party defending the action may reasonably request. The defending Party may not
enter into any settlement, consent judgment or other voluntary final disposition of such action
that admits the invalidity or unenforceability of any Patent licensed hereunder, subjects the
other Party to an injunction or requires the other Party to make any monetary payment without the
prior written consent of the other Party, not to be

 CONFIDENTIAL

49

 

unreasonably withheld by the other Party. The Party undertaking any such defense shall keep
the other reasonably informed of the progress of the action and shall consider the comments and
observations of the other in the proceedings.

     9.6 Patent Infringement Claims.

          (a) Each Party shall notify the other Party promptly in writing of any claim of, or action
for, infringement of any Patents or misappropriation of trade secret rights of any Third Party
that is threatened, made or brought against either Party by reason of the development,
manufacture, use, sale, offer for sale, importation or exportation of the Product in the
Territory.

          (b) In the event of the institution of any suit by a Third Party against either Party for
Patent infringement involving the development, manufacture, use, sale, offer for sale, importation
or exportation by or on behalf of Alpharma, its Affiliates or Sublicensees of the Product in the
Territory after the Effective Date, Alpharma shall be responsible for the defense of any such suit
and, subject to the terms of this Section 9.6, Alpharma shall control such defense. Alpharma
shall select defense counsel and, provided that Alpharma can do so without compromising
attorney-client privilege, regularly consult with Durect and its counsel to keep them reasonably
informed on the progress and status of the suit. Durect shall assist Alpharma and cooperate in
any such litigation at Alpharma’s request and Cost. No settlement, compromise or other
disposition of any such proceeding that subjects Durect to an injunction or requires Durect to
make any monetary payment shall be entered into without Durect’s prior written consent, which
consent will not be unreasonably withheld. Notwithstanding the foregoing, Alpharma shall not have
any obligation to defend Durect against any Third Party Patent infringement suit arising out of
any breach by Durect of its representations and warranties hereunder.

          (c) Alpharma shall be responsible for all Costs to defend any suit that it is responsible for
under this Section 9.6, including all fees and costs of attorneys, expert witnesses and other
out-of-pocket litigation costs and all damages, penalties, court costs, attorney fees and other
payments payable to any such Third Party, whether as a result of any judgment, award, settlement
or otherwise (such liability, “Patent Litigation Losses”); provided, however, Alpharma may
offset [**] percent ([**]%) of all such Patent Litigation Losses

 CONFIDENTIAL

50

 

against any future Royalties due to Durect for Net Sales in such applicable Jurisdiction(s),
provided that any such set-off (by itself or in combination with other set offs) may not reduce
the Royalties to Durect for Net Sales in such applicable Jurisdiction(s) by more than [**] percent
([**]%) in any calendar quarter. Without limiting Durect’s liability for any breach of Durect’s
representations and warranties hereunder, Durect’s sole liability and Alpharma’s exclusive remedy
against Durect for any Patent Litigation Losses shall be Alpharma’s right of offset in accordance
with Section 9.6(c).

          (d) In the event a Third Party threatens suit against either Party for Patent infringement
involving the development, manufacture, use, sale, offer for sale, importation, exportation,
license or marketing of the Product in the Territory, the Parties shall confer with respect to the
appropriate course of action, and if they determine that a declaratory action is warranted, then
with respect to such action, the provisions of this Section 9.6 shall apply thereto with respect
to the prosecution of such action and the defense of any claims asserted in response thereto.

          (e) In the event that either Party becomes aware of a Third Party Patent, under which, in the
good faith reasonable judgment of such Party, it would be advisable to obtain a license to avoid
infringement or potential infringement by the development, manufacture or Commercialization of the
Product in any Jurisdiction, such Party shall promptly notify the other Party. The Parties shall
then confer in good faith with respect to the appropriate course of action. Alpharma shall have
the right to negotiate and obtain such a license and, subject to the terms of this Section 9.6(e)
below and without limiting Durect’s liability for any breach of its representations and warranties
hereunder, Alpharma shall be solely responsible for all costs and obligations under such license
(the “Third Party License Fees”), provided, however, that Alpharma may offset [**] percent
([**]%) of all such Third Party License Fees against any future Royalties due to Durect for Net
Sales in such applicable Jurisdiction(s) provided that any such set-off (by itself or in
combination with other set offs) may not reduce the Royalties to Durect for Net Sales in such
applicable Jurisdiction(s) by more than [**] percent ([**]%) in any calendar quarter. Alpharma
shall provide Durect with complete copies of the license agreement with such Third Party and other
material information in its possession in respect of such technology subject to any
confidentiality provisions imposed by such Third Party.

 CONFIDENTIAL

51

 

     9.7 Patent Term Extensions. Alpharma may select which, if any, Patents other than the
[**] licensed hereunder for which patent term extension, adjustment or restoration or supplemental
protection certificates (together with patent term extensions, adjustments and restorations,
collectively “Patent Term Extensions”) is to be sought or obtained. Subject to the terms
of this Section 9.7, Alpharma will file for all such Patent Term Extensions at Alpharma’s expense,
and Durect will execute such authorizations and other documents and take such other actions as may
be reasonably requested to obtain such Patent Term Extensions, including designating Alpharma as
its agent for such purpose.

     9.8 Prosecution of Durect Trademark. Durect shall use Commercially Reasonable Efforts
to register and maintain, or cause to be registered and maintained, the Durect Trademark in
Jurisdictions as agreed upon by the Parties at Alpharma’s Cost. Durect shall furnish Alpharma with
copies of all substantive prosecution correspondence to and from trademark offices in the Territory
and provide Alpharma a reasonable time to offer its comments thereon before Durect makes a
submission to the relevant trademark office, provided that in the event that delay would jeopardize
any potential rights, Durect shall have the right to proceed without awaiting Alpharma’s comments
on any application or correspondence relating to the Durect Trademark. Alpharma shall offer its
comments promptly, and Durect shall consider in good faith such comments of Alpharma and shall
incorporate such comments if reasonable. Alpharma shall use the Durect Trademark, and all Products
bearing the Durect Trademark shall be manufactured, in accordance with the trademark usage and
quality standards established by the JEC and approved by Durect, such approval not to be
unreasonably withheld nor delayed; provided that, on a Jurisdiction-by-Jurisdiction
basis, the JEC shall, if commercially reasonable, adopt any trademark usage and quality standards
timely proposed by Durect to the JEC prior to the First Commercial Sale in such Jurisdiction.

     9.9 Enforcement of Durect and Product Trademarks. If either Party learns of any
infringement or threatened infringement by a Third Party of the Durect Trademark or a Product
Trademark in the Territory, such Party shall as soon as reasonably practicable notify the other
Party and will provide such other Party with all available evidence of such infringement or
threatened infringement. Alpharma shall have the right, but not the obligation, to institute,
prosecute and control, at its own Cost, any action or proceeding with respect to any infringement
or threatened infringement by a Third Party of the Durect Trademark or any Product Trademark

 CONFIDENTIAL

52

 

in the Territory, by counsel of its own choice and, provided that Alpharma can do so without
compromising attorney-client privilege, shall regularly consult with Durect and its counsel to keep
them reasonably informed on the progress and status of the suit. For any such action to terminate
any such infringement, in the event that Alpharma is unable to initiate or prosecute such action
solely in its own name or it is otherwise advisable to obtain an effective remedy, Durect will join
such action voluntarily and will execute and cause its Affiliates to execute all documents
necessary for Alpharma to initiate litigation and maintain such action. Alpharma will control the
action, including settlement thereof; provided, that no settlement or consent judgment or other
voluntary final disposition of any such action brought by Alpharma to enforce the Durect Trademark
in the Territory pursuant to this Section 9.9 may be entered into without the prior written consent
of Durect, such consent not to be unreasonably withheld, if such settlement would adversely affect
the Durect Trademark (e.g., restrict the rights or admit invalidity). Any damage award or other
consideration resulting from any such action or proceeding shall be retained by Alpharma.

     9.10 Maintenance of [**] Agreements. Until the expiration or termination of
this Agreement, or in the case of the [**] Agreement, until such agreement is assigned to Alpharma,
Durect: (a) shall not breach, or default under the [**] Agreement or [**] Agreement, which breach
or default would give rise, whether immediately or with the passage of time, to termination of the
[**] Agreement or [**] Agreement or to any restriction of Durect’s rights thereunder in a manner
that would adversely affect the rights granted by Durect to Alpharma under this Agreement; and (b)
without the prior written consent of Alpharma, shall not amend or terminate or allow to lapse
(except for the natural expiration of the [**] Agreement in accordance with its terms) the [**]
Agreement or [**] Agreement, if such amendment, termination or lapse would adversely affect the
rights granted by Durect to Alpharma under this Agreement. Alpharma acknowledges that its
sublicense to the [**] is subject to the applicable terms of the [**] Agreement. In addition,
notwithstanding the foregoing, Durect shall not be deemed in breach of this Section 9.10 if such
breach, default or termination of the [**] Agreement is due to Alpharma’s failure to comply with
the terms of the [**] Agreement which are applicable to Alpharma and have been fully disclosed to
Alpharma prior to the Execution Date. [**].

 CONFIDENTIAL

53

 

10. PUBLICATION; CONFIDENTIALITY

     10.1 Notification. The Parties recognize that each may wish to publish the results of
their work relating to the subject matter of this Agreement. However, the Parties also recognize
the importance of acquiring patent protection and other considerations. Consequently, subject to
any Applicable Laws obligating any Party to do otherwise, any proposed publication by any Party
that may disclose Collaboration Inventions shall comply with this Section 10. At least [**] before
a manuscript is to be submitted to a publisher, the publishing Party will provide the other Party
with a copy of the manuscript. If the publishing Party wishes to make an oral or visual
presentation, it will provide the other Party with a summary of such presentation at least [**]
before such oral or visual presentation and, if an abstract is to be published, [**] before such
abstract is to be submitted. Any oral or visual presentation, including any question period, shall
not include any Confidential Information belonging to a Party unless such Party agrees in writing
to such inclusion in advance of such oral presentation.

     10.2 Review. The other Party will review the manuscript, abstract, text or any other
material provided to it under Section 10.1 to determine whether patentable subject matter or
valuable trade secrets of the reviewing Party are disclosed and to assess the accuracy of the
technical content therein. The other Party will notify the publishing Party within [**] of receipt
of the proposed publication if such Party, in good faith, determines that patentable subject matter
or valuable trade secrets of the reviewing Party are or may be disclosed, or if the other Party, in
good faith, believes Confidential Information of the reviewing Party is or may be disclosed. If it
is determined by the other Party that patent applications should be filed in advance of the
proposed publication, the publishing Party shall delay its publication or presentation for a period
not to exceed [**] from the other Party’s receipt of the proposed publication or presentation to
allow time for the filing of patent applications covering patentable subject matter. In the event
that the delay needed to complete the filing of any necessary patent application will exceed the
[**] period, the other Party will discuss the need for obtaining an extension of the publication
delay beyond the [**] period. If it is determined in good faith by a Party that Confidential
Information or proprietary information of such Party is being disclosed, the Parties shall consult
in good faith to arrive at an agreement on mutually acceptable modifications to the proposed
publication or presentation to avoid such disclosure. Any publications (whether written or oral),

 CONFIDENTIAL

54

 

where consistent with customary academic practice, shall acknowledge Durect as the developer
and licensor of the Product.

     10.3 Publicity. Neither Party shall make any public announcement concerning the
existence of or the terms of this Agreement and Durect shall not make any public announcement
regarding the development or Commercialization of the Product in the Territory, without the prior
written approval of the other Party with regard to the form, content and precise timing of such
announcement, except such as may be required to be made by either Party in order to comply with
applicable law, regulations, court order, or tax or securities filings. Such consent will not be
unreasonably withheld or delayed by such other Party. Prior to any such public announcement
requiring the other Party’s prior written approval, the Party wishing to make the announcement will
submit a draft of the proposed announcement to the other Party not less than [**] in advance to
enable the other Party to consider and comment thereon. Failure to respond with comments in writing
prior to [**] before scheduled release shall be deemed approval of such release. Notwithstanding
anything to the contrary in this Agreement, nothing in this Section 10.3 is intended to prohibit
either Party from republishing or restating information that has already been approved by the other
Party for use in a prior press release or public announcement. Alpharma shall notify Durect in
advance (at least [**] in advance if commercially reasonable) of written public announcements or
presentations and shall use reasonable efforts to notify Durect in advance of oral public
announcements, in each case, by Alpharma of material new information regarding the development or
Commercialization of the Product and of public announcements by Alpharma of results of Clinical
Trials. Any written public announcements or presentations shall include a standard statement in a
form agreed to by the Parties stating that the Product has been licensed from Durect.

     10.4 Confidentiality. Except to the extent expressly authorized by this Agreement or
otherwise agreed in writing, the Parties agree that, during the Term of this Agreement and for [**]
thereafter, the receiving Party, its Affiliates and its designees shall, and shall ensure that
their respective employees, officers, directors and other representatives shall, keep confidential
and not publish or otherwise disclose and not use for any purpose, other than the development and
Commercialization of the Product in the Territory, any information including all Know-How furnished
to it by the other Party, its Affiliates or its designees, except to the extent that it can be
established by the receiving Party by competent proof that such information: (i) was already

 CONFIDENTIAL

55

 

known to the receiving Party, other than under an obligation of confidentiality, at the time
of disclosure by the disclosing Party; (ii) was generally available to the public or otherwise part
of the public domain at the time of its disclosure to the receiving Party; (iii) became generally
available to the public or was otherwise part of the public domain after its disclosure and other
than through any act or omission of the receiving Party in breach of this Agreement; (iv) was
disclosed to the receiving Party, other than under an obligation of confidentiality, by a Third
Party who had, to the receiving Party’s knowledge, no legal obligation not to disclose such
information to others; or (v) was independently generated by the receiving Party without reference
to Confidential Information of the disclosing Party (all such information to which none of the
foregoing exceptions applies, and the terms of this Agreement, shall be deemed “Confidential
Information”). Any and all information, data and materials, including any and all
Intellectual Property Rights therein and thereto, owned by a Party shall constitute Confidential
Information of such Party which shall be deemed the disclosing Party with respect to such
Confidential Information for the purposes of this Section 10. Notwithstanding the foregoing, the
obligations of confidentiality under this Section 10.4 regarding any Confidential Information
relating to or containing a Party’s trade secret that has been suitably identified to the other
Party as such shall continue beyond the period set forth in this Section 10.4 (i.e., the Term plus
[**]) so long as the subject matter remains a trade secret.

     10.5 Exceptions to Obligation. The restrictions contained in Section 10.4 shall not
apply to Confidential Information that: (i) is submitted by the recipient to a Regulatory Authority
to obtain Regulatory Approval for the Product; (ii) is provided by the recipient to Third Parties
under confidentiality provisions at least as stringent as those in this Agreement, in connection
with consulting, development, manufacturing, external testing, or Commercialization of the Product
or in connection with a proposed financing transaction, merger, acquisition or other change of
control of a Party or sale of all or substantially all of the assets of a Party; or (iii) is
otherwise required to be disclosed in compliance with applicable laws or regulations or order by a
court or other regulatory body having competent jurisdiction, including ; provided that, if a Party
is required to make any such disclosure of the disclosing Party’s Confidential Information, such
Party will, except where impracticable for necessary disclosures (for example, to physicians
conducting studies or to health authorities), give reasonable advance notice to the disclosing

 CONFIDENTIAL

56

 

Party of such disclosure requirement and reasonably cooperate with the disclosing Party to
secure confidential treatment of such Confidential Information required to be disclosed.

     10.6 Limitations on Use. Each Party shall use, and cause each of its Affiliates and
its licensees to use, any Confidential Information obtained by such Party from the disclosing
Party, its Affiliates or its licensees, pursuant to this Agreement or otherwise, solely in
connection with the activities or transactions contemplated by this Agreement.

     10.7 Remedies. Each Party shall be entitled, in addition to any other right or remedy
it may have, at law or in equity, to seek an injunction, without the posting of any bond or other
security, enjoining or restraining the other Party, its Affiliates and/or its licensees from any
violation or threatened violation of this Section 10.

11. REPRESENTATIONS AND WARRANTIES

     11.1 Representations and Warranties of the Parties.

Each Party represents and warrants to the other Party that as of the Execution Date:

     (a) Such Party is duly organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation and has full corporate power and authority to enter into this
Agreement and to carry out the provisions hereof;

     (b) Such Party has taken all corporate action necessary to authorize the execution and
delivery of this Agreement and the performance of its obligations under this Agreement and has
full power and authority to enter into this Agreement and perform its obligations under this
Agreement;

     (c) This Agreement has been duly executed by such Party and constitutes a valid and legally
binding obligation of such Party, enforceable in accordance with its terms, subject to and limited
by: (i) applicable bankruptcy, insolvency, reorganization, moratorium, and other laws generally
applicable to creditors’ rights; and (ii) judicial discretion in the availability of equitable
relief;

     (d) With the exception of required Regulatory Approvals and HSR clearance, such Party has
obtained, or is not required to obtain, the consent, approval, order, or authorization of any
Third Party, or has completed, or is not required to complete, any registration, qualification,
designation, declaration or filing with, any Governmental Entity, in

 CONFIDENTIAL

57

 

connection with the execution and delivery of this Agreement and the performance by such
Party of its obligations under this Agreement, including any grant of rights to the other Party
pursuant to this Agreement;

     (e) The execution and delivery of this Agreement, and the performance by such Party of its
obligations under this Agreement, including the grant of rights to the other Party pursuant to
this Agreement, does not and will not: (i) conflict with, nor result in any violation of or
default under any instrument, judgment, order, writ, decree, contract or provision to which such
Party is otherwise bound; (ii) give rise to any lien, charge or encumbrance upon any assets of
such Party or the suspension, revocation, impairment, forfeiture or non-renewal of any material
permit, license, authorization or approval that applies to such Party, its business or operations
or any of its assets or properties; or (iii) conflict with any rights granted by such Party to any
Third Party or breach any obligation that such Party has to any Third Party;

     (f) Every officer and scientific employee of such Party has an obligation to assign his or
her inventions to such Party to the extent such inventions are within the scope of his or her
activities for such Party with respect to this Agreement, and all such officers and scientific
employees and every technical consultant retained by such Party to provide services to such Party
has an obligation to maintain the confidentiality of such Party’s confidential information; and

     (g) As of the Effective Date, each Party is in compliance with Section 3.4.

     11.2 Additional Representations and Warranties of Durect. Durect hereby further
represents and warrants to Alpharma that as of the Execution Date:

     (a) Durect is the sole owner of the Product Know-How, Product Patent Rights, [**] in
existence on the Effective Date and has a valid license under the [**], and has the right to grant
to Alpharma the rights granted under this Agreement (including the right to develop, manufacture
and Commercialize the Product in the Territory). To the Knowledge of Durect, the Product Patent
Rights, [**] are valid, in full force and effect and have been maintained to date, and are not the
subject of any interference or opposition proceedings;

 CONFIDENTIAL

58

 

          (b) Other than the [**] Agreement, Durect has not entered into any agreement with any Third
Party pursuant to which royalties or other license fees would be owed on the development,
manufacture or Commercialization of the Product;

          (c) The [**] Agreement and [**] Agreement are in full force and effect. To the Knowledge of
Durect, the parties to such agreements are not in material default or breach of such agreements;

          (d) Except for the [**] Agreement and [**] Agreement, Durect is not party to any agreement
with a Third Party, which if breached by or defaulted under by Durect, or terminated or amended or
allowed to lapse, would adversely affect the rights granted by Durect to Alpharma under this
Agreement;

          (e) Durect has not granted any license, consent, permission or other right or privilege under
the Product Patents Rights, Product Know-How, the [**] or the [**], other than this Agreement.
The Patents listed on Schedules 1.31, 1.62, 1.63 and 1.70 include all Patents currently Controlled
by Durect relating to Product;

          (f) [**];

          (g) [**];

          (h) There are no liens or security interests currently existing on or to the Product
Know-How, Product Patent Rights, [**] or any proceeds thereof that could reasonably be expected to
adversely affect Alpharma’s benefits and rights under this Agreement;

          (i) To the Knowledge of Durect, all of the studies, tests and Pre-clinical and Clinical
Trials of the Product conducted prior to, or being conducted as of, the Execution Date were
conducted, or are being conducted, in accordance with Applicable Laws, and in the case of Clinical
Trials, the then valid cGCP. “cGCP” shall mean the current standards for Clinical Trials for
drugs, as set forth in the FDC Act and applicable FDA regulations (including without limitation 21
C.F.R. Parts 50, 54 and 56) and guidances promulgated thereunder, as amended from time to time;

          (j) Durect has disclosed, shown or made available (e.g., through the electronic data room) to
Alpharma all material information and data (including without limitation all communications with
or from the FDA or any other Regulatory Authority) relating to the

 CONFIDENTIAL

59

 

results of all Preclinical and Clinical studies of the Product conducted by or on behalf of
Durect including, without limitation, with respect to the status and interim results of ongoing
Clinical and Preclinical studies and Regulatory Approval activities; and

          (k) The documentation made available by Durect as requested by Alpharma in connection with
Alpharma’s due diligence in entering into this Agreement, to Durect’s Knowledge is, in all
material respects, true, complete and unredacted (except as expressly noted in such
documentation). Without limiting the generality of the foregoing, to Durect’s Knowledge, all
reports and other data summaries provided to Alpharma by Durect prior to the Effective Date
relating to the Preclinical, Non-Clinical and Clinical studies of the Product accurately represent
the underlying raw data in all material respects. Durect has provided to, or made available for
review by, Alpharma all reports and data collections containing information about adverse safety
issues (including adverse drug experiences) related to the Product of which Durect has Knowledge.

     11.3 Disclaimer of Other Warranties. EXCEPT AS SET FORTH IN THIS AGREEMENT, THE
PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
INCLUDING WARRANTIES OF QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR
NON-INFRINGEMENT.

     11.4 Survival of Representations. The representations and warranties set forth in this
Agreement shall survive indefinitely.

12. INDEMNIFICATION; INSURANCE

     12.1 Indemnification by Durect. Durect shall indemnify, defend and hold Alpharma and
its Affiliates, and their respective directors, officers, employees and agents (each a
“Alpharma Related Party”) harmless from and against any and all damages, losses, judgments,
penalties, fines, settlements, and costs and expenses (including reasonable fees of attorneys and
other professionals) (“Damages”) arising out of Third Party claims that result from any
breach by Durect of this Agreement including breach by Durect of its representations and warranties
hereunder.

 CONFIDENTIAL

60

 

     12.2 Indemnification by Alpharma. Alpharma shall indemnify, defend and hold Durect
and its Affiliates and their respective directors, officers, employees and agents (each a
“Durect Related Party”) harmless from and against any and all Damages arising out of Third
Party claims that result from: (i) any breach by Alpharma of this Agreement, including breach by
Alpharma of its representations and warranties hereunder or (ii) the development or
Commercialization of the Product by Alpharma, its Sublicensees, Affiliates or designees under this
Agreement.

     12.3 Shared Liability. If Damages arise out of Third Party claims that are subject to
indemnification by Alpharma under Section 12.2 and also subject to indemnification by Durect under
Section 12.1, then the Parties shall indemnify each other to the extent of their respective
liability for the Damages. In the event that the Parties cannot agree to their respective
indemnity obligations hereunder, a Party shall be free at any time to seek resolution of the
respective indemnity obligations of the Parties under this Section 12 pursuant to the provisions
set forth in Section 14.12.

     12.4 Indemnification Procedure. Upon receipt by the Party seeking indemnification
hereunder (an “Indemnified Party”) of notice of any action, suit, proceeding, claim, demand
or assessment against such Indemnified Party which might give rise to Damages, the Indemnified
Party shall give prompt written notice thereof to the Party from which indemnification is sought
(the “Indemnifying Party”) indicating the nature of the claim and the basis therefore,
provided that the failure to give such prompt notice shall not relieve the Indemnifying Party of
its obligations hereunder except to the extent the Indemnifying Party or the defense of any such
claim is materially prejudiced thereby. The Indemnifying Party shall have the right, at its
option, to assume the defense of, at its own Cost and by its own counsel, any such claim involving
the asserted liability of the Indemnified Party. If any Indemnifying Party shall undertake to
compromise or defend any such asserted liability, it shall promptly notify the Indemnified Party
of its intention to do so, and the Indemnified Party shall agree to cooperate fully with the
Indemnifying Party and its counsel in the compromise of, or defense against, any such asserted
liability; provided, however, that the Indemnifying Party shall not, as part of any settlement or
other compromise, admit to liability for which the Indemnifying Party is not fully indemnifying the

CONFIDENTIAL

61

 

Indemnified Party or agree to an injunction with respect to activities of the Indemnified Party
without the written consent of the Indemnified Party. Notwithstanding an election by the
Indemnifying Party to assume the defense of any claim as set forth above, such Indemnified Party
shall have the right (at its own Cost if the Indemnifying Party has elected to assume such defense)
to employ separate counsel and to participate in the defense of any claim.

     12.5 Cost of Enforcement. All Costs incurred by an Indemnified Party in connection
with enforcement of its rights under Sections 12.1, 12.2 and 12.3, as applicable, shall also be
reimbursed by the Indemnifying Party (or, in the case of Section 12.3, allocated between the
Parties in accordance with Section 12.3) promptly after final determination that such Indemnified
Party is entitled to such indemnification by the Indemnifying Party.

     12.6 LIMITATION ON DAMAGES. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER,
WHETHER PURSUANT TO THE FOREGOING INDEMNIFICATION OBLIGATIONS OR OTHERWISE UNDER THIS AGREEMENT,
FOR SPECIAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES, INCLUDING BUSINESS INTERRUPTION OR LOST PROFITS,
OR PUNITIVE DAMAGES; PROVIDED, HOWEVER, THIS EXCLUSION IS NOT INTENDED TO, NOR SHALL,
EXCLUDE ACTUAL OR COMPENSATORY DAMAGES OF THE AFFECTED PARTY, INCLUDING SPECIAL, EXEMPLARY OR
CONSEQUENTIAL DAMAGES, OWED TO THIRD PARTIES AS A RESULT OF A THIRD PARTY CLAIM.

     12.7 Insurance. Each Party shall carry and maintain in full force and effect while
this Agreement is in effect reasonable insurance in view of its obligations hereunder but in
amounts no less than that specified for each type:

     (a) Commercial general liability insurance with combined limits of not less than $[**] per
occurrence and $[**] per accident for bodily injury, including death, and property damage;

     (b) Workers’ compensation insurance in the amounts required by the law of the Jurisdictions,
countries or states in which such Party’s workers are located; and

     (c) Products liability insurance with a policy limit of at least $[**] per occurrence and in
the aggregate.

     Each Party hereto shall name the other Party hereto as an “additional insured” on all
commercial and product liability policies relating to the insurance described in Sections 12.7(a)

 CONFIDENTIAL

62

 

and (c). Each Party upon request shall provide the other with evidence of such insurance. Each
Party shall provide to the other 30 calendar days’ prior written notice of any proposed
cancellation, termination, reduction or change in its coverage.

13. TERM AND TERMINATION

     13.1 Term of Agreement. This Agreement shall become effective as of the Effective
Date and remain in effect on a Jurisdiction-by-Jurisdiction basis until the expiration of the
applicable Royalty Term or earlier termination of this Agreement (the “Term”). Upon the
expiration of the applicable Royalty Term in a Jurisdiction (but not upon the earlier termination
of this Agreement), the rights and licenses granted to Alpharma under this Agreement with respect
to the Product in such Jurisdiction shall convert to fully paid-up, non-royalty-bearing, perpetual
rights and licenses.

     13.2 Condition Precedent

     (a) HSR Compliance. Each Party shall use commercially diligent efforts to satisfy
any applicable requirements under the HSR, and the regulations promulgated thereunder, including
by making an initial HSR filing as soon as practicable after the Execution Date. This Agreement
will not be effective until the date (“Effective Date”) of satisfaction of any such
requirements and the expiration or termination of all applicable waiting periods (including any
early termination or extensions thereof). The obligations, rights, duties and liabilities under
this Agreement (except those contained in this Section 13.2 and Sections 10 and 11 of this
Agreement) shall not be effective until the Effective Date.

     (b) Cooperation. Each Party shall cooperate with the other Party in the prompt
preparation, execution and filing of all documents that are required or permitted to be filed
pursuant to HSR, and to notify the other Party upon receipt of any formal or informal requests
for information from any antitrust agency in connection with any filings under HSR. Each
Party shall bear its own Costs with respect thereto (provided, however, the filing fees for HSR,
if applicable, shall be paid by Alpharma).

     (c) Termination Right. If the Effective Date has not occurred within six (6) months
after the Execution Date, notwithstanding that each Party having fulfilled its

CONFIDENTIAL

63

 

obligations under
this Section, either Party has the right to terminate this Agreement without liability to the
other Party by notice in writing with immediate effect.

     13.3 Termination by Alpharma.

          (a) Without Cause. Alpharma may terminate this Agreement without cause upon six (6)
months’ prior written notice at any time. In such event, during the six-month notice period, [**]
provided that it shall not be obligated to [**]; provided that, (i) [**] and (ii)
if [**].

          (b) Safety. If during the development or commercialization of the Product, the
Product becomes subject to one or more Serious Adverse Drug Experiences (as defined below) or
either Party receives notice from a regulatory authority, independent review committee, data
safety monitoring board or another similar Clinical Trial or post-marketing monitoring body
alleging significant concern regarding a patient safety issue, in each case which Alpharma, in
good faith, reasonably believes would seriously impact the long-term viability of the Product,
Alpharma shall have the right, upon [**] prior written notice to Durect setting forth the reasons
therefor, to have the JEC determine whether or not there exists such serious impact on the
long-term viability of the Product and what, if anything, the Parties should do to address the
matter. In the event the JEC is unable to reach consensus on resolution of the matter within [**]
of the matter being referred to the JEC, Alpharma may terminate its rights and obligations under
this Agreement upon written notice so long as Alpharma reasonably believes the patient safety
issue would seriously impact the long-term viability of the Product. During the foregoing notice
and resolution periods, Alpharma may take any actions that it reasonably determines are necessary
to address such safety concerns. For purposes of this Agreement, a “Serious Adverse Drug
Experience” means any adverse drug experience occurring at any dose that results in any of the
following outcomes: death, a life-threatening adverse drug experience, inpatient hospitalization
or prolongation of existing hospitalization, a persistent or
significant disability/incapacity, or a congenital anomaly/birth defect. Important medical
events that may not result in death, be life-threatening, or require hospitalization may be
considered a Serious Adverse Drug Experience when, based upon appropriate medical judgment, they
may jeopardize the patient or subject and may require medical or surgical intervention to prevent
one of the outcomes listed in this definition.

CONFIDENTIAL

64

 

     13.4 Termination for Material Breach. Upon the material breach by one Party under
this Agreement, the other Party shall notify the breaching Party of such breach, and require that
the breaching Party cure such breach within [**] or, in the case of payment defaults, within [**],
or in the case of a breach that cannot be cured within [**], within a reasonable period not
exceeding [**] so long as the breaching party is diligently proceeding to cure such default. In
the event that a material breach by such Party is not cured within the applicable cure period and
without limiting other available remedies, the other Party shall have the right to terminate this
Agreement upon written notice. Notwithstanding the foregoing provisions of this Section 13.4, (a)
the provisions of Sections 4.2(c) and 4.3(d) and not this Section 13.4 shall control the Parties’
remedies and liabilities with respect to the matters set forth therein and (b) in the case of any
bona fide dispute regarding an alleged material breach that is submitted to arbitration pursuant to
Section 14.12, the non-breaching Party shall not have the right to terminate this Agreement
pursuant to this Section 13.4 until a final arbitration award determines that such breach has
occurred and, if such breach is a failure to pay amounts due under this Agreement which payment is
disputed in good faith by the breaching Party, this Agreement shall not terminate pursuant to this
Section 13.4 based on such payment breach if the breaching Party pays the amounts finally
determined to be due, with interest calculated in the manner set forth in Section 7.6, if
applicable, within [**] after the final arbitration award is rendered.

     13.5 Termination for Patent Challenge. In the event that Alpharma or any of its
Affiliates or Sublicensees commences or otherwise pursues, directly or indirectly (or voluntarily
assists Third Parties to do so, other than as required by law or legal process), any proceeding
seeking to have any of the Product Patent Rights, [**] revoked or declared invalid, unpatentable,
or unenforceable, Durect may as its sole remedy terminate this Agreement upon written notice to
Alpharma.

     13.6 Termination for Bankruptcy. Either Party may immediately terminate this
Agreement upon the occurrence of either of the following: (a) the entry of a decree or order for
relief by a court having jurisdiction in the premises in respect of the other Party in an
involuntary case under any applicable national, federal, or state insolvency or other similar law,
and the continuance of any such decree or order unstayed and in effect for a period of [**]; or (b)
the filing by the other Party of a petition for relief under any applicable national, federal, or
state insolvency or other similar law.

 CONFIDENTIAL

65

 

     13.7 Effect of Termination.

     In the event of termination of this Agreement or in the event Durect terminates Alpharma’s
license in any Terminated Country in accordance with Section 4.2(c) or 4.3(d):

          (a) all licenses granted by Durect to Alpharma in Section 3 shall terminate in the Territory
or Terminated Country, as applicable;

     (b) in the Territory or Terminated Country, as applicable, Alpharma shall or shall cause its
Affiliates and Sublicensees, if any, to assign or transfer to Durect, at no Cost (except as
otherwise specifically provided in Section 13.7(e) below and except that, to the extent any such
assignment or transfer to Durect requires more than [**] of effort by Alpharma, its Affiliates
and/or Sublicensees, Durect shall reimburse Alpharma, its Affiliates and/or Sublicensees for any
such efforts in excess of [**] on the same basis that Alpharma reimburses Durect for Durect
Development Costs hereunder), all Regulatory Documentation, Development Data, Regulatory
Approvals, Product Trademarks (and goodwill associated therewith) Controlled by Alpharma or its
Affiliates and Sublicensees, if any, as applicable, that relate to the development, manufacturing,
use or sale of the Product (collectively, the “Product Material);

     (c) if applicable, subject to Section 13.3(b), Alpharma shall continue during the notice
period before termination becomes effective (or if reasonably practicable and agreed to by
Alpharma at such time, allow Durect or its Clinical research organizations (“CROs”) to
continue any ongoing Clinical Trial for which Alpharma has responsibility; and

     (d) if Alpharma has manufactured, or has had manufactured the Product for Clinical Trial or
Commercialization, Alpharma at its option shall either transition the
manufacturing process to Durect or a mutually agreed Third Party CMO or supply the Product to
Durect; provided, that if Alpharma chooses to transition the manufacturing process to Durect or a
mutually agreed Third Party CMO, Alpharma will continue to supply the Product until the completion
of the transition and associated Regulatory Approvals have been received, but in no event for a
period exceeding [**] from the date of termination, and further provided that during any period in
which Alpharma continues to supply the Product to Durect, Durect shall pay Alpharma therefor [**];
provided that, Alpharma shall not be required to establish or have

CONFIDENTIAL

66

 

established any new
manufacturing process in order to satisfy its obligations under this Section 13.7(d) (e.g., if a
commercial scale manufacturing process has not been established, Alpharma shall not be required to
establish or have established such a process); and

     (e) In the event that Alpharma terminates this Agreement pursuant to Section 13.3(a) or
Durect terminates this Agreement pursuant to Section 13.4 above, and if [**] the Product in any
Jurisdiction, then [**] of the Product; and (ii) in the case that [**] in each case received by
[**] as a result of such license; provided, however, notwithstanding the foregoing, [**] under
this Section 13.7(e) once [**].

     (f) Alpharma will cooperate in any reasonable manner requested by Durect to achieve a smooth
transition of the development, manufacturing and Commercialization of the Product to Durect or its
licensees in the Terminated Countries or Territory, as applicable; provided that, to the extent
any such cooperation (including the efforts required of Alpharma, its Affiliates and Sublicensees
under Section 13.7(b)) requires more than [**] of effort by Alpharma, its Affiliates and/or
Sublicensees, Durect shall reimburse Alpharma, its Affiliates and/or Sublicensees for any such
efforts in excess of [**] on the same basis that Alpharma reimburses Durect for Durect Development
Costs hereunder.

     13.8 Post-Termination. Upon and after termination of this Agreement, Durect shall
indemnify, defend and hold harmless the Alpharma Related Parties against any and all Damages
incurred or suffered by any Alpharma Related Party, or with which any of them may be faced, to the
extent arising out of or caused by the development, manufacture, distribution, marketing,
promotion, sale or other use of the Product by or on behalf of Durect or its Affiliates or
licensees after the effective date of the termination.

     13.9 Surviving Provisions. Expiration or any termination of this Agreement shall not
release a party from the obligations to make any payments that were due or had accrued immediately
prior the effective date of such termination (including non-cancelable obligations or commitments
made in good faith prior to notice of termination), and the following Sections of this Agreement
shall survive any expiration or termination of this Agreement for any reason:

(i) Sections 1, 3.3, 7.4, 7.5, 7.6, 9.1, 9.2(b), 9.2(d), 10.4-10.7, 11, 12, 13.1, 13.7-13.9 and 14,
and

(ii) Sections 9.6(a)-(d) (with respect to events occurring during the Term of this Agreement).

 CONFIDENTIAL

67

 

14. MISCELLANEOUS PROVISIONS

     14.1 Relationship of Parties. Nothing in this Agreement is intended or shall be
deemed to constitute a partnership, agency, employer-employee or joint venture relationship between
the Parties. No Party shall incur any debts or make any commitments for the other, except to the
extent, if at all, specifically provided herein.

     14.2 Assignment. Neither Party shall assign this Agreement or its rights or
obligations hereunder without the express written consent of the other Party hereto, except that
either Party may assign or transfer this Agreement and its rights or obligations hereunder without
the consent of the other Party to (i) an Affiliate, (ii) any assignee of all or substantially all
of its business or assets relating to the subject matter of this Agreement, or (iii) its successor
in the event of its merger, consolidation or involvement in a similar transaction. An assignment
or transfer by a Party pursuant to this Section 14.2 shall be binding on its successors or assigns.
No such assignment or transfer shall be valid or effective unless done in accordance with this
Section 14.2.

     14.3 Books and Records. Any books and records to be maintained under this Agreement
by a Party or its Affiliates shall be maintained in accordance with GAAP.

     14.4 Further Actions. Each Party shall execute, acknowledge and deliver such further
instruments, and do all such other acts, as may be reasonably necessary or appropriate in order to
carry out the purposes and intent of this Agreement.

     14.5 Notice. Any notice, request or other communication required or permitted to be
given under or in connection with this Agreement shall be deemed to have been sufficiently given if
in writing and personally delivered, facsimile transmission (receipt verified), electronic
mail or overnight express courier service (signature required), prepaid, to the Party for
which such notice is intended, at the address set forth for such Party below:

In the case of Durect, to:

Durect Corporation

2 Results Way

Cupertino, CA 95014

Attention: General Counsel

Facsimile No.: (408) 777-3577

Telephone No.: (408) 777-1417

CONFIDENTIAL

68

 

In the case of Alpharma, to:

Alpharma Ireland Limited

Arthur Cox Building

Earlsfort Terrace

Dublin 2, Ireland

Attention: Director

Facsimile No.: 353 1 618 0618

Telephone No.: 353 1 618 0000

with a copy to:

Alpharma Inc.

440 Route 22

Bridgewater, NJ 08807

Attention: General Counsel

Facsimile No.: (908) 566-4139

Telephone No.: (908) 566-3800

or to such other address for such Party as it shall have specified by like notice to the other
Party, provided that notices of a change of address shall be effective only upon receipt thereof.
If delivered personally or by facsimile transmission, the date of delivery shall be deemed to be
the date on which such notice or request was given. If sent by overnight express courier service,
the date of delivery shall be deemed to be the next business day after such notice or request was
deposited with such service.

     14.6 Use of Name. Except as otherwise provided herein, Durect, on the one hand, and
Alpharma on the other hand, shall not have any right, express or implied, to use in any manner the
name or other designation of the other or any other trade name, trademark or logos of the other for
any purpose, unless consented to in writing by the other Party.

     14.7 Waiver. A waiver by any Party of any of the terms and conditions of this
Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition
for the future, or of any subsequent breach hereof. All rights, remedies, undertakings,
obligations and agreements contained in this Agreement shall be cumulative and except as
specifically provided herein none of them shall be in limitation of any other remedy, right,
undertaking, obligation or agreement of either Party.

CONFIDENTIAL

69

 

     14.8 Counterparts. This Agreement may be executed simultaneously in any number of
counterparts, any one of which need not contain the signature of more than one Party but all such
counterparts taken together shall constitute one and the same agreement. This Agreement, to the
extent signed and delivered by means of a facsimile machine (or pdf-file attachment to Email),
shall be treated in all manner and respects and for all purposes as an original agreement or
instrument and shall be considered to have the same binding legal effect as if it were the original
signed version thereof delivered in person.

     14.9 Severability. When possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision
of this Agreement is held to be prohibited by or invalid under applicable law, such provision will
be ineffective only to the extent of such prohibition or invalidity, without invalidating the
remainder of this Agreement.

     14.10 Amendment. No amendment, modification or supplement of any provisions of this
Agreement shall be valid or effective unless made in writing and signed by a duly authorized
officer of each Party.

     14.11 Governing Law. This Agreement shall be governed by and interpreted in
accordance with the laws of the State of New York without regard to conflicts of law principles.

     14.12 Dispute Resolution.

     (a) The Parties recognize that a bona fide dispute as to certain matters may from time to
time arise during the Term of this Agreement that relate to any Party’s rights or obligations
hereunder. In the event of the occurrence of any Dispute (as defined below), either Party may, by
written notice to the other, have such Dispute referred to its highest ranking officer for
attempted resolution by good faith negotiations within [**] after such notice is
received. If either Party desires to pursue arbitration under paragraph (b) below to resolve
any such Dispute, unless expressly provided for otherwise herein, a referral to such executives
under this paragraph (a) shall be a mandatory condition precedent. Said designated officers as of
the Effective Date are as follows.

     For Durect: Chief Executive Officer

     For Alpharma: Senior Vice President, Alpharma Pharmaceuticals LLC

CONFIDENTIAL

70

 

In the event that they shall be unable to resolve the Dispute by consensus within such [**]
period, then the Dispute shall be finally settled by binding arbitration as provided below.

          (b) Except as expressly otherwise provided in this Agreement, any dispute arising out of or
relating to the interpretation of any provisions of this Agreement or the failure of either Party
to perform or comply with any obligation of such Party pursuant to this Agreement or the breach,
termination or validity hereof (a “Dispute”), shall be exclusively and finally settled by
arbitration under the Commercial Arbitration rules of the American Arbitration Association
(“AAA”) then in effect (the “Rules”), as modified by the terms set forth in this
Section 14.12(b). The place of arbitration of any Dispute shall be in New York, New York. Such
arbitration shall be conducted by three arbitrators, one appointed by each of Alpharma and Durect
and the third selected by the party-appointed arbitrators. Each arbitrator shall be neutral and
impartial and shall have relevant experience in the pharmaceutical industry. Alpharma and Durect
shall make their respective appointments within [**] of receipt by the respondent of a copy of the
demand for arbitration. Such party-appointed arbitrators shall select the third arbitrator within
[**] of the appointment of the second arbitrator. If any arbitrator is not timely appointed, on
the request of any Party such arbitrator shall be appointed by the AAA in accordance with the
listing, striking and ranking provisions in the Rules. The arbitrators shall render an award as
expeditiously as possible; if practicable, within six months after the appointment of the third
arbitrator. Any award rendered by the arbitrators shall be final and binding upon the Parties.
Judgment upon any award rendered may be entered in any court having jurisdiction, or application
may be made to such court for a judicial acceptance of the award and an order of enforcement, as
the case may be. Except as provided in Section 12.5, each Party shall pay its own Costs of
arbitration, provided, however, the fees and expenses of the arbitrators shall be equally shared
between Alpharma and Durect. Any Costs
(including attorney’s fees and expenses) incident to enforcing the award shall be charged
against the Party resisting such enforcement. This Section 14.12 shall not prohibit a Party from
seeking preliminary injunctive relief in aid of arbitration from a court of competent jurisdiction
in the event of a breach or prospective breach of this Agreement by any other Party which would
cause irreparable harm to the Party seeking such relief. Without prejudice to such provisional
remedies as may be available under the jurisdiction of a court, the arbitrators shall have full
authority to grant provisional remedies and to direct the Parties to request that any

CONFIDENTIAL

71

 

court modify
or vacate any temporary or preliminary relief issued by such court, and to award damages for the
failure of any Party to respect the arbitrators’ orders to that effect.

     14.13 Compliance with Laws. Each Party shall review in good faith and cooperate in
taking actions to ensure compliance of this Agreement and the Parties’ activities hereunder with
all Applicable Laws. Each Party shall provide the other Party such reasonable assistance as may be
required for the Party requesting such assistance to comply with all Applicable Laws necessary to
permit the Parties to perform hereunder and to exercise their respective rights hereunder.

     14.14 Force Majeure. Except where expressly provided for herein, neither Party shall
be held liable or responsible to the other Party nor be deemed to be in default under, or in breach
of any provision of, this Agreement for failure or delay in fulfilling or performing any obligation
of this Agreement to the extent that such failure or delay is due to Force Majeure, and without the
willful wrongdoing, recklessness or gross negligence of the Party so failing or delaying. For
purposes of this Agreement, “Force Majeure” is defined as causes beyond the reasonable
control of the Party, including acts of God; changes in regulations or laws of any government; war;
terrorism; civil commotion; destruction of production facilities or materials by fire, flood,
earthquake, explosion or storm; labor disturbances; epidemic; and failure of public utilities or
common carriers. In the event that the ability of Durect or Alpharma to perform its obligations
under this Agreement, as the case may be, shall be so affected, the affected Party shall
immediately notify the other Party of such inability and of the period for which such inability is
expected to continue. The Party giving such notice shall thereupon be excused from such of its
obligations under this Agreement as it is thereby disabled from performing for so long as it is so
disabled and the [**] thereafter. To the extent possible, each Party shall use Commercially
Reasonable Efforts to minimize the duration of any Force Majeure.

     14.15 Entire Agreement. This Agreement including schedules and exhibits thereto,
including the Development Plan together with all other future written agreements entered into by
the Parties and specifically made a part of this Agreement, constitute the entire agreement between
the Parties with respect to the subject matter of this Agreement and supersede all prior agreements
and understandings, both oral and written, between the Parties with respect to the subject matter
of this Agreement.

 CONFIDENTIAL

72

 

     14.16 Parties in Interest. All of the terms and provisions of this Agreement shall be
binding upon, inure to the benefit of and be enforceable by the Parties hereto and their respective
permitted successors and assigns.

     14.17 No Third Party Beneficiaries. Except for rights and obligations specifically
referred to herein that apply to Affiliates, sublicenses or licensees of the Parties, nothing in
this Agreement is intended to confer on any Person other than Durect or Alpharma any rights or
obligations under this Agreement, and there are no intended Third Party beneficiaries to this
Agreement.

     14.18 Descriptive Headings; Certain Terms. The descriptive headings of this Agreement
are for convenience only, and shall be of no force or effect in construing or interpreting any of
the provisions of this Agreement.

     14.19 Fees and Payments. All fees and payments made by one Party to the other under
this Agreement shall be deemed non-refundable unless expressly provided to the contrary herein.

     14.20 No Implied Licenses. Except as specifically and expressly granted in this
Agreement, no rights or licenses to any intellectual property rights are granted by either Party to
the other, by implication, estoppel or otherwise, and each Party specifically reserves all its
rights with respect to any intellectual property rights not specifically granted hereunder.
Furthermore, unless expressly provided otherwise herein, each Party may use and practice its own
Intellectual Property Rights, technology and data in any manner not inconsistent with the terms of
this
Agreement without the consent of the other Party and without obligation to notify the other
Party of its intended use.

     14.21 Information for Financial Reporting. In addition to the reports provided by
Alpharma pursuant to Section 7.1, Alpharma agrees to provide to Durect good faith non-binding
estimates of Net Sales and other information reasonably necessary for Durect to estimate the
Royalties in each calendar month following the commercial launch of the Product within [**]

 CONFIDENTIAL

73

 

after
the end of such month. Alpharma shall not have any liability for any inaccuracy in any such
report. Each such report shall constitute Confidential Information of Alpharma and shall not be
disclosed by Durect to any Third Party other than to Durect’s accountants and auditors in
confidence, except for any disclosures as may be required to be made by Durect in order to comply
with applicable law, regulations, court order, or tax or securities filings.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

CONFIDENTIAL

74

 

IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed by its duly
authorized representative as of the day and year first above written.

	 	 	 	 	 
	 	Durect Corporation

 	 
	 	By:  	/s/ James E. Brown
 	 
	 	 	Name:  	James E. Brown 	 
	 	 	Title:  	President and Chief Executive Officer 	 
	 
	 	Alpharma Ireland Limited

 	 
	 	By:  	/s/ Keith Bernius
 	 
	 	 	Name:  	Keith Bernius 	 
	 	 	Title:  	Director 	 
	 

 CONFIDENTIAL

75

 

GUARANTEE

     In consideration of Durect Corporation, a corporation organized and existing under the laws
of the State of Delaware (“Durect”) entering into the foregoing Agreement (the
“Agreement”), Alpharma Inc., a corporation organized and existing under the laws of the
State of Delaware (“Alpharma Parent”), hereby irrevocably and unconditionally guarantees
to Durect, as principal and not as surety, the performance of Alpharma Ireland Limited, a
corporation organized and existing under the laws of Ireland (“Alpharma”) of all
obligations of Alpharma to Durect under the Agreement.

     Durect may enforce its rights under this Guarantee without first exercising any other
remedy or right that Durect may have; provided that, prior to enforcing its
rights under this Guarantee, Durect shall have first made demand for performance upon Alpharma
and Alpharma thereafter shall have failed to perform for the applicable cure period set forth in
Section 13.4 of the Agreement. If Durect decides to proceed to first exercise any other remedy
or right, or to proceed against another party, Durect retains all of its rights under this
Guarantee.

     Alpharma Parent hereby agrees that any and all disputes, claims, actions or proceedings
arising out of the execution, delivery or performance of this Guarantee shall be subject to
arbitration in accordance with Section 14.12 of the Agreement.

     This Guarantee shall survive the expiration or other termination of the Agreement and shall
survive and apply regardless of any amendments, waivers, extensions, modifications or other
changes in the obligations of Alpharma under the Agreement.

	 	 	 	 	 
	 	 	Alpharma Inc.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Jeff Campbell
	 

	 	 	 	 
	 

	 	Its:
	 	Jeff Campbell, Executive Vice President and 
Chief Financial Officer
	 

	 	Date:
	 	September 19, 2008

CONFIDENTIAL

 

 

Schedule 1.24 — Durect Development Costs

Development Costs are equal to the sum of the following, in each case incurred by Durect in the
performance of the Development Program: (i) labor cost of Durect’s research and development
personnel charged as set forth below, (ii) direct outside expenditures, and (iii) capital asset
expenditures.

[**]

CONFIDENTIAL

 

 

Schedule 1.31— [**]

[**]

CONFIDENTIAL

 

 

Schedule 1.60- Product Description

[**]

A total of four pages have been omitted pursuant to a request for confidential treatment.

 CONFIDENTIAL

 

 

Schedule 1.62—Product Patent Rights

[**]

 CONFIDENTIAL

 

 

Schedule 1.63—[**]

[**]

CONFIDENTIAL

 

 

Schedule 1.70—[**]

[**]

A total of two pages have been omitted pursuant to a request for confidential treatment.

 

 

Schedule 2.1- Initial Members of JEC

Durect
MEMBERS

[**]

Alpharma
MEMBERS

[**]

SECRETARY            TBD

 

 

Schedule 2.2 — Initial Members of JDC

Durect MEMBERS

[**]

Alpharma MEMBERS

[**]

 

 

Schedule 2.6 – Alliance Managers

Alpharma: [**]

Durect: [**]

 

 

Schedule 4.3 –Mandatory Major Market Jurisdictions

The United Kingdom

Germany

France

Spain

Italy

Japan

 

 

Schedule 4.4 –Notice of Orphan Drug Status

[**]

A total of three pages have been omitted pursuant to a request for confidential treatment.

 

 

Schedule 6.2 -Exemplary Royalty Calculation

[**]

A total of two pages have been omitted pursuant to a request for confidential treatment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}]]